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Foreword from Professor Michael Parker 
 
In December 2012, I was asked by the Chief Medical Officer for England, 
Professor Dame Sally Davies, to chair an Ethics Advisory Group on Genomics 
leading up to the establishment of the 100,000 Genomes Project. We were 
given the task of identifying the key ethical challenges that would need to be 
addressed as part of ensuring the successful and ethical completion of the 
Project. We were also invited to make recommendations about how these 
challenges might be resolved. It was clear from the outset that the 100,000 
Genomes Project was going to need to be innovative, not only in its 
application of genomics at scale in the clinical setting and in research, but 
also in its development of an approach to good ethical practice in genomics. 
One of the most important recommendations of the Advisory Group was that the successful 
completion of the 100,000 Genomes Project and the sustainable introduction of genomics into the 
NHS were going to depend upon the development of an effective model for the achievement of valid 
consent in genomics at the clinical-research interface. We were aware at that time that whatever 
model of consent was adopted by the project would need to be complemented by regular 
evaluation and would be likely to need to be modified over time informed by good quality evidence 
about its effectiveness and acceptability to patient-participants. 
Against this background, I am absolutely delighted to have been asked to write a foreword to this 
important report, which presents the findings of a study led by three of the Genomic Medicine 
Centres on the national experiences of three stakeholder groups: revealing the first evidence we 
have of these for patient-participants in the 100,000 Genomes Project, recruiters, and Patient and 
Public Involvement groups in the NHS.  
This is a vitally important and timely piece of research as we review the participant materials in the 
light of the emerging available evidence. We were reassured to see that (for example) the majority 
of responding participants endorsed the length and content of the information materials. The 
majority of responding recruiters similarly endorsed the content, but prioritised brevity of these 
materials, which we will note for future iterations.  
We warmly welcome this contribution to the evidence base for consent in genomics in clinical and 
research practice. 
 
  
  
  
Professor Michael Parker 
Professor of Bioethics and 
Director, The Ethox Centre 
University of Oxford  
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Foreword from Professor Sue Hill 
 
The 100,000 Genomes Project is at the heart of our efforts to transform 
healthcare in England from a one-size-fits-all system to a targeted, 
personalised approach where patients will get individualised treatment 
based on their unique characteristics. NHS England has established 13 NHS 
Genomic Medicine Centres to cover the country delivering an end-to-end 
genomic medicine pathway and they are enabling the participation of 
patients and family members in the 100,000 Genomes Project with their 
informed consent; collecting samples to extract DNA; capturing clinical 
information to inform the interpretation of the genome sequence; and 
establishing the infrastructure to make genomic medicine a routine part of NHS care.  
The information consenting process itself is key to the patient experience and to supporting 
healthcare professionals. This has been identified consistently as an area in which there is scope for 
improvement if we are to transform ways of working and build whole genome sequencing as part of 
the genomic testing repertoire into routine patient pathways. 
I am delighted that three of the NHS GMCs have led this piece of work to evaluate the consent 
materials.  
I would like to say thank you to everyone who contributed to the evaluation, recognising that the 
insight gained from recruiting professionals, participants and patient and public involvement (PPI) 
groups has provided a more robust evidence base from which to revise the materials.  
We are very pleased to note that for example, 87% of staff who completed this survey felt 
‘confident’ or ‘very confident’ in being able to provide a quality consent experience. We will be 
working with colleagues at Genomics England to take on recommendations such as addressing the 
literacy needs and providing easy to read versions of the materials.  
We have also recently committed to resourcing a national 100,000 Genomes Project Information 
Line, operated initially by South West NHS GMC. This directly supports the recommendation in the 
report to explore ways of ensuring that recruiting staff have appropriate time to discuss the issues 
raised in the Participant Information Sheet (PIS) with participants, where this is needed. 
This project is hugely important to the international community who are undertaking similar projects 
and considering the introduction of Whole Genome Sequencing into routine clinical care. The 
appropriateness of informed consent of patients and listening to participants is vital to 
implementation and success.  
  Professor Sue Hill OBE 
Chief Scientific Officer 
NHS England 
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Evaluation Summary 
 
This report details the outcome of a snap-shot national service evaluation which aimed to gather 
feedback and determine the facilitators and barriers related to the perceptions and processes of 
those involved in consent conversations during the initial stages of recruitment into the 100,000 
Genomes Project. Data collection was undertaken between May and July 2016. 
In 2013, The Prime Minister launched the 100,000 Genomes Project to bring the predicted benefits 
of genomics to NHS patients. Genomics England, a company owned and funded by the Department 
of Health, was set up to deliver this flagship project which will sequence 100,000 whole genomes 
from NHS patients by 2017. Its four main aims are: 
• To create an ethical and transparent programme based on consent; 
• To bring benefit to patients and set up a genomic medicine service for the NHS; 
• To enable new scientific discovery and medical insights; and 
• To kick start the development of a UK genomics industry. 
The 100,000 Genomes Project focuses on patients with a rare disease and their families, and 
patients with cancer. The project was the first to be processed through the Health Research 
Authority as a National Health Service Transformational Project. As such it has a hybrid status; that 
of requiring research governance but also transforming clinical practice. 
The first samples for sequencing were taken from patients living in England in April 2015. 
Recruitment for rare disease patients had been ongoing for 12 months, and 2 months for cancer 
patients prior to this evaluation. 
A commitment to evaluate the consent materials was outlined in section 12.2.1 of the 100,000 
Genomes Project approved Protocol v 2.0, dated February 2015: ‘Genomics England intends to 
further evaluate and revise its literature, and patient and public materials at the 10,000 participant 
recruitment point’ (Available from https://www.genomicsengland.co.uk/library-and-resources/).  
The development and methodology of this National Consent Evaluation is detailed in a separate 
document, the ‘Service Evaluation Schedule’, available from www.genomicsengland.co.uk/consent-
evaluation. 
Three stakeholder groups were involved from across 13 NHS Genomic Medicine Centres (Figures 1 
and 2). This social and behavioural science research follows a mixed methods design with parallel 
mixed methods data analysis culminating in the development of meta-inferences (conclusions 
generated through an integration of the inferences that were obtained in the three strands of the 
study). 
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Figure 1 Three stakeholder groups were involved: patient and public involvement groups associated with Genomic Medicine 
Centres, Health Professional recruiters and 100,000 Genomes Project participants themselves. 
 
Figure 2 Thirteen Participating Genomic Medicine Centres 
 
Participants 
n=174/1196 
(14.6%) 
Documentation 
& Consent 
Interaction NHS GMC 
PPI Groups 
n=5 
34 members 
 
HP 
Recruiters 
n=58/161 
(36%) 
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General 
• Good communication was established with the Genomic Medicine Centres and all engaged 
in some way with this 8 week snap-shot evaluation project. 
• The evaluation succeeded in eliciting views from three stakeholder groups involved in the 
consent process. Quantitative survey results should be viewed with caution due to low 
response rate and possible sources of bias. 
• On occasion views diverged between and within stakeholder groups, however there were 
also similarities. 
• The consent process varied as to how it was implemented between different GMCs and 
there was evidence of local process adaption. 
This snap-shot evaluation (mid-way through the 100,000 Genomes Project) showed that there were 
differing opinions both within and between stakeholder groups. This means that when considering 
the development of materials to help facilitate consent, it is important to bear in mind that how they 
are perceived and utilised will differ in relation to context and the individual participant’s 
information needs.  The results need to be considered alongside on-going and published research as 
well as ongoing policy debate regarding consent for whole genome sequencing. 
There was support for the supplementary materials developed to help with the consent process, 
such as the information leaflet, animations and flip-chart. These were viewed as being useful in 
preparing patients for the consent discussion. Suggestions were provided concerning how to support 
NHS recruiting staff, including on-going training. Overall, 87% of staff who completed this survey 
(who represented 36% of active recruiting staff at the time of the evaluation) felt ‘confident’ or ‘very 
confident’ in being able to provide a quality consent experience. Although not necessarily 
representative of all participants, due to the response rate of 14.6%, those 100,000 Genome Project 
participants who returned a feedback postcard (n = 172) were extremely satisfied with the consent 
materials and process they experienced.  Participants in the focus groups were also supportive of the 
information included in the consent material. There were aspects of the consent materials and 
consent process that received positive comment from all stakeholder groups.  
However, evidence of where the materials could be improved was also found. Concern was raised by 
recruiters and focus group members regarding the length and readability of the participant 
information sheets (PIS) and consent forms, and they proposed specific changes that could be made. 
These are detailed in the appendices of the ‘National Service Evaluation Project: Background 
Document’ which is available to Genomics England for review when implementing changes to the 
consent material or process.  
Half or more of the recruiters perceived that participants ‘sometimes’, ‘often’ or ‘very often’ 
experienced difficulty with certain sections of the consent forms, especially the sections ‘taking 
part’, ‘samples’, ‘access to my data and confidentiality’, and ‘results’.  Approximately half of the 
recruiters reported that participants ‘often’ or ‘very often’ needed ‘extra explanation to understand 
the project’, had specific needs related to ‘low levels of literacy’ and ‘increased levels of anxiety 
related to current health situation’. All stakeholder groups felt it was important to keep most of the 
current informational content in some way within the materials but wished for changes to the PIS 
and consent documents in terms of presentation and readability. 
Figures 3 provides an infographic overview of some of the evaluation findings.  
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The following recommendations are made to Genomics England and are 
based on the evidence from this evaluation. It is expected that Genomics 
England will take forward the conversations with partners across the 
healthcare system such as NHS England, Genomic Medicine Centres and 
Health Education England. 
Recommendations 1 to 8 are suggestions on elements to maintain, recommendations 9 to 17 are 
issues Genomics England may consider changing in relation to project documentation, and 
recommendations 18 to 26 are linked to project processes. Each recommendation is linked back to 
the data collected by providing the recommendation number alongside the evidence within the 
synthesis tables in Chapter 4. 
Things to maintain (1-8) 
1. The current range of consent materials i.e. participant information sheet (PIS), consent forms, 
information leaflet, animation/flip chart. 
2. The current wording in the PIS relating to explanations of scientific and genomic terminology in 
line with recommendation 9. 
3. The majority of the information content within the PIS (responses from participants and most 
focus group members support this, along with 50% of recruiters). 
4. The PIS both in paper form and on-line (not just on-line). 
5. The key point boxes and colour on the forms. 
6. Continue to develop accessibility to consent materials for low vision patients.  
7. The ability of participants to opt-in and opt-out of the search for additional findings. 
8. The facility for health professionals to have the time to adequately discuss and answer patient 
questions prior to the consent decision. 
Changes to consider - Project Documentation/Accessibility (9-16) 
9. Improve the presentation and readability of the PIS and consent forms in the following ways.  
9.1 Reduce the density of words. 
9.2 Reduce replication of text especially the sections between the consent form and PIS and 
also after the key point boxes. 
9.3 Use pictures/diagrams where possible. 
9.4 Work with participants/100,000 Genomes Project National Participation Panel/PPI 
groups/Ethics Advisory Committee to review new material/changes to assist in approaching 
standards such as the Plain English Guidelines and the Accessible Information Act. 
9.5 Reduce the length of the consent form. 
9.6 Review the terminology (e.g. main findings, additional findings) used across all project 
materials, including written and animation/video to assist with understanding the project 
specific terms. 
9.7 Include a source for standard definitions/concepts (this could also be available for 
recruiters) for example, a glossary of definitions of both scientific and project terminology 
and ensure these are consistent with descriptions in the text. 
10. Continue to support non-English speakers by promoting the use of existing NHS translation 
services when discussing project documentation with potential participants. 
11. Produce an ‘Easy Read’ version of the PIS and consent form that could be used for participants 
with reduced intellectual ability or those for whom English is a second language (possibly the ‘young 
adults’ PIS could be adapted for use with this group). 
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12. Provide an audio/video of the content of the PIS and consent form for participants who find 
access to the written word difficult. 
13. Promote the Genomics England website as a place to access information (presented in a variety 
of formats) about taking part in the project. 
14. All materials to adopt consistent use of terms relating to anonymisation, when  it is linked-data, 
when unlinked and clarify at which point this occurs e.g. at what point companies might have access. 
15. More information to be available to participants regarding the concept of additional findings and 
especially ones of reproductive significance, including the timescale for results and future contact. 
16. To clarify the audience for the tri-fold information booklet and if it is for use with patients, 
review the booklet and add definitions of terminology used.  
Changes to consider - Process of Consent Interaction (17-22) 
17. Explore ways of ensuring that recruiters have appropriate time to discuss the issues raised in the 
PIS with participants, where this is needed. 
18. Support recruiters through on-going consent training including how to manage questions from 
participants regarding support with communication in their families and social/psychological 
support. 
19. Support recruiters with the information technology systems for registering participants and 
logging samples. 
20. Provision of more publicity materials to help recruitment into the project. 
21. A staged consent process for cancer participants if anxiety levels are high at the time of 
diagnosis. Possibly consider adapting the PIS and consent forms for this patient group. 
22. During the further integration of whole genome sequencing into routine NHS clinical care, the 
following issues need careful consideration and planning. 
22.1 Maintaining adequate time for consent discussion. 
22.2 Consider carefully the changes required for the transition of Whole Genome 
Sequencing consent from the research environment into routine clinical care. 
22.3 Supportive and appropriate local mechanisms for receipt of main findings and 
additional findings (results). 
22.4 Support and updating of staff providing patient support.  
22.5 Consideration of consent timing within the routine care pathway (especially cancer 
patients and their families). 
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Figures 3 Infographic Summary of Evaluation 
 
National Evaluation Project Report | November 2016 
 
Page 11 of 55 
 
  
National Evaluation Project Report | November 2016 
 
Page 12 of 55 
 
1 Background 
 
1.1 Context of Consent in the 100,000 Genomes Project  
 
In April 2015, the first set of consent materials were issued to Genomic Medicine Centres. The 
materials and consent process had been developed by Genomics England after two years of piloting, 
policy and clinical discussion, including engagement and involvement activities with patients, 
clinicians and other groups.  Some of the key engagement and advice reports for the period prior to 
2015 are detailed below and are available on the Genomics England website.  
• Advisory Group on Ethics letter to Dame Sally Davies (Chief Medical Officer) 22nd March 2013 
- Professor Michael Parker (Chair of the advisory group on ethics). 
• Managing incidental and pertinent findings from Whole Genome Sequencing (WGS) in the 
100,000 Genome Project. A discussion paper from the Public Health Genomics Foundation. 
April 2013.  
• Potential Participant Literature: Research Report, November 2014. RandallFox. 
• What do patients with rare genetic conditions think about whole genome sequencing in the 
NHS? Research Findings for the 100,000 Genomes Project, November 2014. Genetic Alliance 
UK. 
• Ethical issues relating to involvement of cancer patients in the 100,000 Genomes Project. 
Qualitative Research Findings, October 2014. GfK (Market Research Company). 
• Research on Genomic Data Sharing. Qualitative research report, September 2014. Solutions 
Research (Market Research Company). 
The consent materials and process also had to satisfy legislation such as the Data Protection Act 
(1998) and the Human Tissue Act (2004), as well as the Mental Health Act (2007) (Department of 
Health 2007), in order to provide for consent to be sought for certain uses of tissue or data.  
The 100,000 Genomes Project is unusual in that it is not purely a research study, but is embedded in 
the patient’s own clinical care team, issuing results back to participants and their families. Therefore 
the consent process and documentation had to be designed to work to inform participants about 
both the clinical utility and the research aspects of participation. 
“Drawing on relevant guidance and exemplars of good practice, the participant materials (i.e. letters 
of invitation, Patient Information Sheets, and assent and consent forms) have been developed in 
accordance with the key principles in the Key Ethical Principles document and Ethical Governance 
Framework, and with the advice of the Ethics Advisory Committee, with comments from the Science 
Committee, and other stakeholders and the appropriate guidance.”  
100,000 Genomes Protocol, February 2015. 
1.2 Context of the National Service Evaluation Project 
Some NHS Genomic Medicine Centre (GMC) Patient & Public Involvement (PPI) groups commented 
on the consent documentation which was issued to GMCs at the start of the project (April 2015). 
They suggested that it would benefit from an evidenced review, which this service evaluation aimed 
to provide. 
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Genomics England set out a phased framework for the evaluation and adaptation of the consent 
documentation and process. Phase 1 consisted of seeking feedback from PPI leads and clinicians 
within the NHS GMCs as recruitment began. This resulted in the development of additional items of 
participant information materials, for optional use, which aim to respond to (potential) participants’ 
different needs.  The following amendments and additions were made to the consent materials 
between April 2015 and March 2016: 
• A short 4 page introduction leaflet (executive summary) 
• A tri-fold awareness-raising pamphlet 
• Editing of the Research Ethics Committee (REC) approved consent materials to correct 
mistakes and inconsistencies 
• A Prezi presentation for participants, as an alternative to print media 
• Materials for partially sighted and blind participants 
• Flip chart for use during consent discussions 
 
1.3 Shared purpose and scope of project 
Genomics England engaged in discussions regarding how to gather evidence which could be 
presented to the Research Ethics Committee (REC) alongside any suggested changes.  
In August 2015 Genomics England created an Evaluation Project Steering Group, which reviewed an 
outline proposal led by North West Coast GMC in collaboration with two GMC PPI leads. This 
described an evaluation which would provide the opportunity for receiving feedback from three 
stakeholder groups (participants, recruiters and GMC PPI members). The project team and Genomics 
England staff would work together, using the NHS Change Model of the NHS Improving Quality 
programme as a framework to identify a shared understanding as to the reason for the evaluation, 
as well as the process by which results would feed back into change to the consent materials or 
process (NHS Improving Quality 2015).  
In March 2016 the evaluation project schedule was agreed, 
(https://www.genomicsengland.co.uk/consent-evaluation) and was approved by the REC on 18th 
May 2016 (14/EE/1112 Substantial Amendment 8).  A commitment to evaluate the consent 
materials was outlined in section 12.2.1 of the 100,000 Genomes Project approved Protocol v 2.0, 
dated February 2015 (Available from https://www.genomicsengland.co.uk/library-and-resources/).  
As such this schedule is in accordance with the Protocol v 2.0 as approved by the NRES REC, and 
requires no change to be made to this. 
A commitment was also made to publish a public report outlining the findings of this evaluation, 
alongside other evidence, to make recommendations concerning any amendments required. 
The Genomics England Steering Group agreed part-funding, alongside funding offered by the 
Innovation Agency (NWC) and a collaboration partnership between the University of Central 
Lancashire, University of Birmingham and Imperial College London. 
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The NHS Genomic Medicine Centres’ National Service Evaluation of the Consent Process and 
Participant Materials used in the 100,000 Genomes Project had three aims: 
1. To evaluate participant materials (consent documentation) 
2. To evaluate the consent discussion process  
3. To provide evidence to inform the development of consent materials and processes for the NHS in 
this area 
The service evaluation covers three key stakeholder groups: 
 
• NHS GMC PPI group members 
• Healthcare professionals (recruiters), and  
• 100,000 Genomes Project participants 
 
The aim being that views could be collated and any problems resolved for the benefit of future 
participants, although re-design of the consent materials is beyond the remit of this service 
evaluation. 
The results of this research project have been submitted to the Genomics England Ethics Advisory 
Committee. This independent committee advises the Genomics England Board on the ethical aspects 
of everything Genomics England does. It scrutinises what information patients should receive about 
their results, as well as the policies on consent. This work forms part of Genomics England’s wider 
evaluation of the 100,000 Genomes Project consent documentation and consent discussion process.  
2 Methods 
2.1 Evaluation Methodology 
This project is a developmental evaluation, defined as: 
“Where innovation assumptions are revised over time, with the results that the goal of the 
intervention may be changed. This type of formative evaluation also facilitates close to real-time 
feedback to the intervention team. It assists with trying out new ideas, documenting activities and 
their short-term consequences, identifying processes and outcomes as they emerge and helping 
people make sense of them” (Dozois, Langlois et al. 2010). 
The evaluation was a mixed methods service evaluation and used a triangulation approach for 
gathering evidence (Creswell 2011). 
The design is parallel multi-strand mixed methods. In this design the qualitative and quantitative 
phases (activities) were designed to answer related aspects of the same research question (Teddlie 
2009). “In this design the strands of analysis are independent, each providing an understanding of 
the phenomenon under investigation. These inferences made on the basis of the results from each 
strand are integrated or synthesised to form meta-inferences” p 266 (Teddlie 2009). One advantage 
of mixed methods research is that of providing an assortment of divergent views (Greene 2007). The 
parallel tracks analysis was undertaken according to the markers of quality and excellence for each 
method (qualitative or quantitative) (Figure 4). 
Specific areas of interest covered both the rare disease and cancer 100,000 Genomes Project 
pathways, and included: 
• Consent discussion process - the context within which the discussion occurs. 
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o Are participants given appropriate time to read information about the project and 
discuss with others before making their decision to participate?  
o How long does the consent interview last? 
o What facilities are available to the participant and health professional? 
• Participant information sheets – content, visual impact, layout, logical order/flow of topics.  
• Participant consent forms – content, visual impact, layout, logical order/flow of topics. 
• Health Professional Support. 
o Are the recruiting health professionals supported in providing the participant with 
an explanation of the project and answering participant questions? 
o How easy or difficult do they find consenting participants for this project? 
 
Working with three different stakeholder groups has permitted evaluation of the consent experience 
in multiple geographic sites and from contrasting perspectives. Materials for data collection were 
piloted and field tested for face validity and were amended appropriately. It was anticipated that the 
materials would be used by all NHS GMC sites to feed data back to the Service Evaluation Project 
Team for analysis and synthesis. Each site had the option to include either or both rare disease and 
cancer participants. 
 
The intervention being evaluated: The 100,000 Genomes Project consent materials and consent 
discussion process in use February to July 2016. 
The project started with 10 pre-determined areas of focus, divided into two main categories. The 
areas of focus were extrapolated by the Project Team from their discussions with the Steering 
Group, the NHS GMC PPI group network, the EAC, NHSE, and other wider stakeholders.  
Project Documentation    
1. Logical Flow  
2. Complexity of project structure (complex project – consent material is therefore complex)  
3. Complexity and consistency of use of scientific/genomic terminology  
4. Issues related to main findings, additional (opt in/opt out) and incidental findings  
5. Data security (privacy) and data sharing (private companies) – including impact on insurance  
 
Process of Consent Interaction 
6. Nature and timing of approach to participant – (personal/letter) 
7. Seeking broad vs. specific consent  
8. Time taken for participant to consent (at initial contact, after several contacts) 
9. Consent Interview – location/length/ease 
10. Flexibility vs. pre-determined pathway 
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Figure 4 Project Design - Parallel multi-stand mixed methods design  
 
 
 
 
                  
                Activity 1                      Activity 2                                       Activity 3                                                                                                
(Patient & Public Involvement)     (Health Professionals)                        (Participants) 
               Qualitative        Quantitative & Qualitative                            Quantitative 
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Experimental Stage  
(Methodological) 
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Experimental Stage 
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Recommendations 
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2.2 Focus Group Methods 
 
The NHS GMC PPI groups’ focus group activity aimed to elicit feedback on consent material, process, 
and ease of use of the current participant documentation in place during the snap-shot survey time 
period.  
The focus group enquiry concentrated on the following four topic areas: 
Topic 1. Logical Flow of consent documentation 
Topic 2. Complexity of project structure  
Topic 3. Seeking broad consent for additional findings 
Topic 4. Transformation and sustainability 
 
NHS England contacted the NHS GMC Clinical Directors and they, in collaboration with the NHS GMC 
PPI Leads Network, nominated a local contact, a nominated PPI lead, for their NHS GMC. The 
nominated PPI leads collaborated with NHS England on how best to facilitate convening the focus 
groups with GMC PPI group members. Criteria for focus group membership are detailed in the 
research schedule document. The research team asked local PPI leads to send invitations to 
individuals who had prior knowledge of the 100,000 Genomes Project, who were not necessarily 
participants, but ideally had worked with the GMC providing PPI input. An evaluation project 
participant information sheet and a consent form together with the 100,000 Genomes Project 
participant material were sent to potential participants prior to the focus groups. Prior to 
commencing the focus group, the consent forms were collected together with a short socio-
demographic questionnaire. Focus group participants were provided with travel expenses for 
attending the meeting, in line with INVOLVE guidelines; refreshments and lunch was also provided. A 
‘thank-you’ voucher (£25) was also sent after the event to each member. 
All focus groups were digitally recorded, subject to the participants completing the written consent 
form. Recordings were professionally transcribed. Data derived was grouped thematically within the 
four topic areas above and, where relevant, the other pre-existing areas which have been identified 
from previous patient and public research concerning the consent materials. 
Data was analysed by Markella Boudioni at Imperial College London using the qualitative 
methodology of thematic analysis (Braun and Clarke 2006). This is a qualitative method aiming to 
answer the evaluation questions and is not a theoretically based qualitative analysis.  The 
documents that were distributed to participants can be found in the project Schedule document 
available from https://www.genomicsengland.co.uk/consent-evaluation/. 
 
2.3 Health Professional Survey Methods 
The aim of the survey was to elicit the opinions of NHS GMC health professionals who are actively 
recruiting participants, and focused on the consent materials and consent discussion process in place 
during the February to March 2016 time period.   
NHS England contacted the Clinical Director of each NHS GMC and asked them to nominate a 
member of their GMC who would act as a local contact for the health professional recruiter survey. 
The NHS GMCs sent an invitation email to their recruiters, including an evaluation project participant 
information sheet for health professionals and a link to the anonymous survey, which was protected 
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by a generic password.  The GMCs supplied the number of recruiting health professionals to whom 
they sent the survey link. 
The survey questions were piloted and amended accordingly. The survey contained closed and open 
ended questions and took about 10-15 minutes to complete. The quantitative questions were 
analysed by descriptive statistics using the SPSS package (IBM Corp 2013). Where possible, 
responses from open text questions were grouped by themes or are provided verbatim. Data-
analysis of the health professional survey occurred independently of the analysis of the focus 
groups, but was concurrent with analysis of the participant survey. 
The health professional survey, introductory email, participant information sheet and survey 
questions can be found in the project Schedule document  
 
2.4 Participant Feedback Methods 
The Clinical Director of each GMC was asked to name a local contact within the NHS GMC who would 
be able to facilitate the distribution of participant survey postcards to recruiting health 
professionals.  
Each NHS GMC was asked to estimate how many participants they expected to consent during the 
2month evaluation period. The NHS England team supplied each GMC with a pack containing two 
sets (rare disease participants and cancer participants) of numbered postage paid survey postcards 
(Figure 5), which had a unique postcard number linked to their NHS GMC. This number does not link 
to the patient’s clinical or 100,000 Genomes Project identifiers. The participant survey was 
anonymous. 
The recruiting health professionals were provided with briefing notes and asked to explain the 
survey to the 100,000 Genomes Project participants for whom they countersigned a consent form. 
The participant was asked if they wish to take part in the survey. If they did, they were handed a 
survey postcard before leaving their consent interview. 
The aim of this postcard distribution strategy was to calculate a response rate based on the number 
of signed consents uploaded to the OpenClinica system over the period (monitored by Genomics 
England) vs. the number of postcards returned by participants during the snap shot survey date 
window.  
The postcard stated the aim of the evaluation and confirmed that all feedback is anonymous. The 
reference number on the postcard refers to the centre recruiting the individual; the individual survey 
number does not link back to any personal identification. Participant information about the Service 
Evaluation was printed on the postcard and was also explained verbally by the health professional 
presenting the postcard. Consent was inferred by the participant returning the postcard.  
Participants were also given the option to complete the survey on-line by entering their unique 
postcard number. The question set was identical on the on-line option, apart from one additional 
question which allows the participant to provide more open comments. 
To optimise accessibility and inclusion the website option facilitated options such as large font and 
could also be used with text readers. The postcards were returned to the Service Evaluation Project 
Team for analysis.  
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The survey contained 15 closed and one open question and took about 3-5 minutes to complete. 
The quantitative questions were analysed by descriptive statistics using the SPSS package (IBM Corp 
2013). Where possible, responses from open text questions were grouped by themes or are 
provided verbatim. Data-analysis of the participant survey occurred independently of the focus 
groups, but was concurrent with the health professional survey.  
The documents that were distributed to participants can be found in the project Schedule 
document. 
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Figure 5 Participant Postcard – Suspected Cancer (C card) and Rare Disease (R card) Participants 
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3 Results 
 
This section presents the results from each stakeholder group, these results are then combined and 
presented in Chapter 4, Synthesis. 
 
3.1 PPI Focus Groups 
Basic demographics are presented followed by results of the four topic areas and additional barriers 
and facilitators. 
Description & socio-demographics 
Five focus groups of 5-8 members took place during May/July 2016 at various locations linked with 
ten out of the thirteen GMCs, and covered rural and urban localities. 
The characteristics of the 34 focus group members varied. There were groups with 100,000 
Genomes Project participants, members of patient groups - specific or non-specific to the project -  
and mixed groups. One group was conducted with patients and relatives/carers of people with rare 
diseases; all other groups included both patients with cancer, rare conditions, and relatives/carers of 
people with rare diseases. The majority were males and females between 45-64 and 65-74 years old, 
with only two groups including younger adults aged 25-44 years old. Members resided in a variety of 
locations; they were mainly White British with the exception of London members.  
Experience of the 100,000 Genomes Project 
The experience of Focus Group members varied: One group consisted of 100,000 Genomes Project 
participants/patients with rare conditions and their relatives. Four groups were mixed condition 
groups involving Project participants and members of other groups; one group did not involve any 
Project participants. 
Participants of the 100,000 Genomes Project: A few of the 100,000 Genomes Project participants 
with rare conditions were also involved with other projects, such as Biobanking and Tissue Banking; 
they suggested the Project had a clearer remit and benefits than other projects (FG A, FG E).   
100,000 Genomes National Participant Panel: A few focus group members were members of the 
Panel. They were critical about its first meeting; the contribution/expectations from them were 
unclear (FG A, FG E). However, they were optimistic as they could see a ‘physical research goal’ (FG 
A).  
Four topic areas for Focus Group enquiry 
Topic 1. Logical flow of consent documentation 
Topic 2. Complexity of project structure 
Topic 3. Seeking broad consent for additional findings 
Topic 4. General transformational and sustainability issues 
 
Topic area 1 - Logical flow of consent documentation 
 
General 
There were differing opinions about the consent material, but few members found the material 
adequate. Consensus that it was adequate and ‘it covered what it should cover’, was reached in only 
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one group (FG A); members felt that the format and the layout of the information sheets and 
consent forms with the different colours, bold letters, boxes and key points were helpful in 
highlighting specific issues. Members of other groups liked the ‘clean’ presentation and colours (FG 
B, FG E), the subtitles in a question format, the key points in boxes of the information sheets, and 
boxes in the consent forms (FG B). Interestingly, those with positive opinions about the consent 
material were mostly 100,000 Genomes Project participants. 
Within the other groups, some members though the material was appropriate, good and fit for 
purpose (FG D); that people may want different types and level of information, thus difficult to 
provide for everyone (FG C). One member said ‘it strikes a good balance managing expectations’ (FG 
E).  
Other members thought the information in general was too wordy (FG A, FG B, FG D), dense and dry, 
with a lot of jargon and inaccessible language (FG A, FG C): ‘they are typical medical research leaflets 
and feel cold’ (FG D). Members also found the material not ‘user friendly’, and not meeting the 9 or 
13 year old literature standards (FG C, FG E). Concerns about the forms’ design, layout and style 
were also raised; some thought the angle of the documents was rather negative and not selling the 
benefits of the project (FG D, FG E). Another suggested a shift from ‘creating a legacy’ to ‘why am I 
doing this’ and personal and family benefits (FG C). In one group there was a consensus that the 
overall emphasis should be on early detection, prevention, treatment and management (FG D). 
 
Participant Information Sheets (PIS) 
There were differing opinions about the PIS, discussed in all focus groups, but only a few members 
were satisfied with the flow of information. Members in one group said the forms were clearly laid 
out and no more difficult than many other official forms (FG E); two members of another thought 
the information and its presentation ‘covers its purpose’ (FG D).  
The majority of members had a number of comments: the PIS were too wordy, lengthy (FG B, FG C) 
or information dense (FG E). It was recognised however that there is no easy answer to this, as 
consent needs to be fully informed (FG E). Potential problems and difficulties in understanding for 
most English speakers (FG E), but also for non-native English speakers (FG C) were discussed. 
Members highlighted a gap about referring to emotional support, regarding both available support 
and the process (FG D). Members also suggested further explanations and clarifications of 
scientific/genomic language were needed, i.e. sequencing (FG A, FG B, FG D, FG E). Many other 
suggestions about language and more accessible/lay explanations were made (FG B, FG D, FG E), and 
are detailed in the ‘National Evaluation Project: Background Document’ available from the Project 
team or Genomics England on request. 
Consent forms 
Some members in one group liked that the consent forms were broken down clearly into different 
sections to sign (FG D). But another group thought the information included was not sufficient, not 
easy to read or understand (FG E). Although there were fewer comments in general about the 
consent forms, a few language and editing suggestions were made (FG D, FG E).  
Opt-in and Opt-out forms 
Some language suggestions were also made (FG D). Members said that ‘additional findings’ should 
be explained so people knew what they were consenting to.  
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Suggestions 
Suggestions included simplified language, i.e. clear plain English (FG A, FG B, FG D), and accessible, 
easy to understand information (FG A, FG B), with the use of more visual material - pictures, charts 
and diagrams - (FG A, FG B), e.g. a diagram with the pros/cons of each topic (FG B). Some examples 
would be useful to provide context, such as the likelihood of additional findings (FG E). As visual 
material would not be suitable for those with visual impairments, other formats should be 
developed (FG A). 
All ‘jargon’ should be removed, and clarifications may be needed to make the material more user 
friendly, i.e. the description of ‘genomic medicine’ with an example (FG C). Clarification and 
explanation of scientific/genomic language, i.e. ‘genome’ and ‘genomic medicine’, and consistency 
across the different documents was suggested (FG A, FG B, FGD), together with more explanation of 
other terms (i.e. clinical trials, carrier status) (FG B, FG E). These could be explained further in the 
text or with a box at the end of the PIS (FG B). Alternatively, an extra leaflet could define these 
terms, including description and explanation of other bodies/structures pertinent to the research, 
such as ‘teams’ (FG C). The addition of a glossary was strongly suggested by most groups (FG A, FG B, 
FG C, FG E).  
The language could be changed positively to sell what the project would do in future and its benefits, 
perhaps adding success stories and a paragraph about emotional support (FG A, FG D). 
Figure 6 Logical flow of documentation 
 
Topic area 2 - Complexity of project structure  
 
General 
In general, it was recognised as a complex project (FG A, FG C, FG E) and genome exploration as a 
difficult concept to understand (FG E). The complexity of all material, clarity, consistency of 
language, and cross-referencing presented earlier also add to the complexity. Other elements were 
highlighted, i.e. changing your mind later (FG B), the availability of genetic testing anyway (FG E). 
Only a few members felt the project is quite straightforward (FG C, FG E), ‘the project itself is fairly 
simple, it’s the consequences that have the complexity’ (FG C). 
Rare conditions and cancer 
The differences between rare conditions and cancer were highlighted, e.g. in terms of time scale of 
diagnosis (FG E), the associated differences in the consent process and timing in the patient pathway 
‘I think, for what they are, the form [PIS] is quite clearly laid out. At the end of the day to take part in the project 
you have to tick all of these boxes and you can’t argue or seek exemption on this element or that element….’                                               
GMC PPI Group member, parent of child with rare disease, non-participant 
‘…I didn’t think the language was very accessible…I think given that it was an introduction out of nowhere… It 
wasn’t in clear English…I think it could have been written in more plain English. It was a bit dry as well so it wasn’t 
appealing…I think this was also selling us something, if you like, but it didn’t do a great job of it because it already 
wanted to buy.’                     100,000 Genomes Project participant, patient with rare disease       
 ‘I really think if you’ve got a leaflet, of some sort, that gives it in an easy read form, and you’d probably read it 
yourself, ‘now I understand and now I’ll go onto these’. To me it’d be a welcoming thing, ‘Don’t be put off by all 
this paperwork. We are obliged to give you this information’, and spell it all out in a lighter format and then have 
the forms.’                                                GMC PPI Group member, patient with cancer, non-participant 
 
National Evaluation Project Report | November 2016 
 
Page 25 of 55 
 
(FG B, FG D, FG E). Patients with cancer and rare conditions and their families may have different 
views of the Project (FG B, FG E); they need different kind of counselling and follow up (FG E). Those 
with rare conditions have potentially more to gain from this work (FG E); the need to find a 
cure/help their families was recognised (FG A, FG B, FG E).   
Consent process – 100,000 Genomes Project participants 
For participants, the consent process was variable, depending on the Trust, locality and condition 
(FG A). For some people with rare conditions, the process was smooth and fast; the majority 
received information by post, a few were contacted by phone first, followed by an appointment (FG 
A). Other people, either with cancer or rare condition, received a clear simple invitation email (FG B). 
Others were told their eligibility by their clinician and then received the information by post (FG A). 
One participant mentioned an open day for all patients who could potentially be recruited (FG C). 
Examples of good practice included professionals explaining the information verbally and spending a 
lot of time with participants (FG A, FG E) - including people with dyslexia and visual impairment 
conditions (FG A). 
Consent process – Non-participants of the 100,000 Genomes Project 
For non-participants, it was unclear what the consent process entailed (FG C, FG E), if people could 
be self-referred or were referred by their clinicians (FG E). They thought the project would generate 
many questions, i.e. about the impact on treatment, and involvement of family members (FG E). It 
was recognised as a complex project that would require explanations by a health professional (FG E).  
One focus group member raised concerns about the process and the point of their pathway at which 
patients were asked to participate; he cited examples when people were asked to participate ‘within 
5 minutes of a breast cancer diagnosis, urging caution in sensitive areas (FG C). 
Complexities regarding carrier status, additional findings and mental capacity 
It was acknowledged that anything with the potential to involve others requires ‘extra thought’, that 
people are individuals and want to know different things (FG B). Someone questioned the extent of 
‘knowing’ in terms of likelihood of transmission of a disease (FG B). Relevant to this were issues 
about mental capacity; a member, who was also a 100,000 Genomes project participant, brought 
the example of his elderly mother who was unable to consent, but he had lasting power of attorney. 
It was unclear how these cases are handled (FG A).  
Suggestions 
The importance of the interaction, professionalism and competency of professionals taking consent 
was stressed (FG C, FG E). Recruitment should be reassuring; the onus should be on recruiters having 
enough time to provide appropriate information (FG C). Written information was considered 
essential, so people can take it away; but the project would need explaining in person by a health 
professional as most people would prefer to listen rather than going through the written 
information (FG C, FG E).  
Members were not clear that the forms are available online through the 100,000 Genomes website. 
Some members would like to be able to read the information and sign the consent form online and 
not through their clinical teams (FG A). 
The availability of support, counselling or ‘tips or advice’ for how to broach this topic or break such 
news to affected family members was discussed (FG B, FG D). There should be strong 
recommendations to discuss this with family members at the point of PIS. Support should be made 
available at a local level; the support process and level should be made clear to potential 
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participants (FG B, FG D).  It was suggested that this is likely to increase participation and retention 
(FG B).  
In addition, more emphasis should be placed on explaining data security issues and clarifying the 
benefits of participating to potential participants (FG C, FG D). 
Figure 7  Complexity of project structure 
 
Topic area 3 - Seeking broad consent for additional findings 
 
General 
Opinions were variable about additional findings; people are individuals and want different things 
(FG A). More information was suggested, i.e. what additional findings are, examples and glossary (FG 
E). 
Online availability of opt-in and opt-out additional findings forms  
It was unclear if the forms were also available through clinical teams (FG B, FG D). Thus, there were 
concerns about them being available online only and potential drawbacks, i.e. equipment, 
technology, time, and reduced access for many (FG B, FG D). Someone questioned the clinical teams’ 
ability to provide forms and suggested a downloadable form to be retained (FG D). Other 
suggestions were individual GMCs being made responsible for the collection and retention of this 
information, i.e. through GMC nurses (FG B, FG D); another was a freepost service to Genomics 
England (FG B). 
The majority would like easy access to both online and paper versions (FG C, FG D); paper versions 
could be given with the participation pack (FG C). Most members of one group agreed that some 
people might make a rash decision; having the option of changing one’s mind in a quick and easy 
way such as downloading/sending off a form ‘wouldn’t be conducive to a rational and well 
considered choice’ (FG C). One member suggested an online ‘request form’ and not a download; two 
others described this as ‘too convenient’; they would welcome a consultation around opting-in or 
out (FG C).  
Information about additional conditions available online 
In three groups, members felt - as additional findings are not clear - unsure about how to answer the 
question posed in the group about information being available online (FG A, FG C, FG E). They were 
confused about whether the list of additional findings was fixed, or updated (FG E). They did not feel 
knowledgeable enough to make clear suggestions (FG A). 
‘…it’s quite a difficult concept for people to understand because it’s not a classic health service thing where 
if you’ve got X you go Y and you get some treatment. It’s a different mind-set…it is a different philosophical 
mind set. I think it’s very different.’                 GMC PPI Group member, patient with cancer, non-participant 
‘… some of the participants in this project, it is the only way - or only avenue they have to find the name or 
a potential cure for their disease either for them or their family…Because people feel a duty to their sons, 
their daughters, their granddaughters.’    GMC PPI Group member, unspecified condition, non-participant  
‘…So if you’re given a result that you’re a carrier, if you are given a result that you may be prone to a cancer 
in the future, there’s no mention here of any support you might be given to understand or to support you 
through the emotional difficulties that you may get from those results. I think that is very important.’                 
Patient Group member linked with GMC, patient with rare disease, non-participant 
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Responses of those who would like to have information was variable; most found the online list of 
additional conditions sufficient (FG C). Others would like to have ‘all’ information available online, 
with links to further information (FG A), and information about the ‘added value’ of additional 
findings (FG D). Others would like to know what additional findings have been found, the 
percentages linked with other conditions (FG C), potential trends and geographical variations (FG D). 
Figure 8 Current process: Opting-in or out of receiving additional findings 
 
The majority of members would like the choice of opting-in or out of their original consent decision 
(FG A, FG C, FG D, FG E); they also liked the option of doing it online. In two groups, there was strong 
agreement on this (FG D, FG E); ‘people need to understand what they sign up to when they opt in’, 
as it has important implications (FG E) and ‘patient choice’ is an element of the NHS (FG D). 
In one group, and if they had one option only, members reached a consensus after a long discussion 
for opting-in for additional findings (FG B). For some members of other groups opting-in was also the 
preferred option (FG A, FG C, FG E); a member felt that one should always be presented with the 
option of opt-in, so people are conscious about what they are consenting to (FG C). Only one 
member felt that opting-out was better, as it would be best for recruitment (FG C).  
 
Topic area 4 - General transformational and sustainability issues 
 
General overview of the 100,000 Genomes Project  
100,000 Genomes Project participants or carers had a positive view about the project and similar 
transformational projects (FG A, FG B, FG E). Other expert patients/members of patient groups, but 
non-participants of the 100,000 Genomes Project, were overall more sceptical (FG D, FG E). 
The consent process being embedded with the participants’ disease pathway 
Members said that currently the consent process of the 100,000 Genomes Project and their disease 
pathway are ‘divorced’, ‘parallel but not linked’ (FG A). However, they could see links in the future, 
i.e. with diagnosis/treatment available and a card/records linked with the condition (FG A). 
Some members felt it is viable to be embedded in the normal pathway for patients; it is for ‘the 
greater good’ and it is the NHS’ duty to adopt and adapt it (FG C). One member considered the 
project vital to reduce unnecessary intervention and improve treatment (FG C). Another thought it 
would have to be separate; expansion should be taken slowly to learn from findings (FG D).  
Another felt that although it is a good project overall, it is disorganised and disjointed, with too 
much administration and not enough collaboration between the different units (FG D). Extra 
‘I’m one of those people who just wants it all, I would love it…So I say, ‘put it all out there’, but don’t throw it 
in people’s faces. Have the links there for the people who want to trawl through and drill down… it would be 
important to also make sure that there were adequate links about where the information is going to be, 
basically who might buy it, who might be using it, and what they might be doing too. If they’re going to have 
access to the information then they jolly well need to put something about commercial organisations who 
are working with the data…’                             100,000 Genomes Project participant, patient with rare disease 
 ‘There is still this element of patient choice. You cannot take away patient choice, it is fundamental thing of 
our statutory rights, you have to have choice. You can’t just take it away from people.’  
Patient group member linked with GMC, patient with rare disease, non-participant 
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reassurance should be offered that anxieties and limitations around the consent process and 
consent material would be eliminated (FG B, FG D).  
Participants of one group suggested recruitment should become an established part of the cancer 
pathway, an option at the ‘first given opportunity’ e.g. along with biopsy sampling. This may be 
supported with integration of the project into existing cancer or rare disease databases (FG B).   
Concerns about the logistics of the project were discussed in another group, i.e. continuity after the 
pilot, availability of long-term staff and healthcare teams, and provision of feedback information in 
the long-term (FG E). Communication and coordination with GPs was also suggested, i.e. Information 
Technology linkage between specialists and GPs (FG E). Members questioned the project’s impact on 
patients’ care pathways in practice, and provision of appropriate feedback and support to members, 
including emotional support (FG E). This would depend on professional competency and capacity; ‘as 
long as things are clear at each step of the project and it works smoothly’, people would have trust 
and confidence. Appropriate support and information about its provision, e.g. peer support groups, 
coffee mornings, should be available to members (FG E). 
The future of such projects 
Most members could see the benefits of such projects (all FGs). Members generally thought this kind 
of research should be embedded for the sake of scientific progress, will kick start new initiatives and 
will help the NHS and patients (FG D). Some recognised such projects as ‘the way forward’ (FG B), as 
exciting, with a wider impact, and extra benefits (FG D). All members of one group recognised the 
importance of such projects to explore new knowledge and answer questions; there is a ‘huge 
educational requirement about the possibilities of genetic testing’ and ‘we must plough ahead with 
genetics health research, can’t know how data will be used’ (FG E). One member could see a 
contribution to family and future generations of those with rare and genetic diseases and 
highlighted their unique position, how their experience makes them ‘grateful’ for the project and 
more likely to oblige in the information and consent process (FG C).  
Potential drawbacks included data insecurity, as ‘genomic information may not be very secure in the 
future, and may be widely used and shared’; blaming people for health states, preventing people 
having children, denying insurance etc. (FG E). Ethical implications and who makes decisions on 
access to and use of information, i.e. if NHS services become more privatised, were also discussed 
(FG E). Other members mentioned the high costs and the risk of creating an expensive field of 
personalised medicine (FG B, FG E), and the provision of appropriate emotional and psychological 
support (FG E). 
Members felt that whether or not such projects have a viable future as part of routine care in the 
NHS depends on whether they show clear benefits, confidence in people’s data being secure, 
confidence and trust in new projects and technologies (FG C). Their future is highly dependent on 
the NHS and ‘whether it remains a united national, centrally controlled entity that is not privatised 
and remains accessible to all’. Any future developments should be done with caution, and with 
regular public and transparent reporting on progress throughout the project’s life (FG C). 
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Figure 9 Transformational and sustainability issues 
 
Additional barriers and facilitators 
 
Introductory Leaflets – flow, complexity, consistency of scientific/genomic terminology 
The three-fold leaflet and suggestions for improvement and accessibility was discussed extensively 
(FG D, FG E). The leaflet was thought to include redundant sentences and negative statements (FG D, 
FG E); emphasis was suggested being put on treatment and prevention (FG D). 
Concerns about consistency in language and information provided were raised, i.e. three-fold leaflet 
and ten-page leaflet (FG A, FG C, FG E). The third category of invited participants with ‘severe 
infections’ referred to in the ten-page leaflet was questioned (FG C, FG E).  
Accessibility and other formats 
Availability of material in other formats, i.e. audio (FG A, FG B) and visual (FG B) were discussed; 
there was a consensus in one group that there are many accessibility issues to these materials (FG 
D). They are not accessible for the majority of English speakers, non-English speakers, and people 
with learning disabilities or dementia; in addition, they don’t have sections for interpreters or carers 
(FG A, FG D). 
An ‘Easy Read’ two-page document with key points in plain English, available alongside the other 
material, on paper and online, creating two-levels of information, was suggested (FG A, FG B, FG D). 
Commercial organisations and for-profit companies 
Concerns were raised in two groups about commercial and for-profit companies’ involvement, i.e. 
questioning pharmaceutical companies’ role, the Project’s ‘money making’ aspect, private 
companies purchasing the data to develop products to be sold to the NHS, potential forcible 
disclosure of findings by insurance companies (FG C, FG D). A member suggested clarification of the 
term ‘insurance provider’ on the PIS to specify health insurance or company insurance (FG C). The 
difference in a patient consenting from an ‘altruistic’ position as opposed to making money for the 
NHS or external companies was also highlighted (FG C). In addition, it was considered unfair for 
100,000 Genomes Project participants to pay to access their own data (FG D). 
‘If they were to create a system where they gave you a card, for example, or something even with a barcode on 
or a link to something, so that you could go to your professional and say ‘My mum has taken part in the 
100,000 Genomes Project…Look there are the findings.’…So that they can use it and that would help my 
descendents and the greater good as well…’        100,000 Genomes Project participant, patient with rare 
disease 
‘Just focusing on the rare diseases, when we left hospital with my daughter we were told that in 70% of cases 
you’d never find out why she was this way. I’d like to know what that percentage is now and will be in the 
future. So just the way it’s going to get answers for people has to be a good thing…finance and the right 
government will needs to be there, and once you get a diagnosis you need the support from the nurses and 
doctors.’                                              GMC PPI Group member, parent of child with rare disease, non-participant   
‘…We’ve got to plough ahead with genomics and what it can do for us and medicine in our future. That’s the 
most important. You can’t keep saying, ‘Well the insurance company might get this’, they might very well but 
I’m more concerned about my future health and that of my family, and other people’s families…’  
GMC PPI Group member, patient with cancer, non-participant  
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Lack of publicity and awareness 
Members overwhelmingly identified the lack of publicity as an on-going barrier (FG B, FG C, FG E); 
one disliked the idea of ‘Joe public spending money and no one knows what’s going on’ (FG C). This 
may affect participation: ‘participants will be going in cold’ (FG E). 
They suggested TV and advertisements in magazines (FG B), GPs as well as hospital clinics (FG E) with 
more leaflets being provided directly by clinics (FG B); and the possibility to consent online (FG A). 
The use of social media, i.e. Facebook and twitter, was suggested to reach younger generations (FG 
A).  
Data security (privacy) and data sharing (private companies) – Including impact on insurance 
Data protection and data sharing were discussed briefly in three focus groups (FG A, FG C, FG D). 
Members were concerned about data security, potential entry points and overseas transfer (FG A, 
FG D). Other concerns were breaching confidentiality (FG B), and the language of data sharing, i.e. 
anonymised or pseudo-anonymised (FG A), anonymised or de-identified data (FG D). Who may 
misuse the data, the influence of genomics companies, information sharing with GPs, and the impact 
of the results on care were also queried (FG B, FG D, FG E).  
Summary 
• 10 out of 13 GMCs were involved in arranging 5 regional focus groups (FGs) which were 
attended by 34 patient representatives or members of the public associated with the GMCs. 
• There was agreement between the FGs that the consent documentation was long and 
difficult for members to understand; suggestions included more pictures, diagrams, and a 
glossary. 
• There was support from some FG members to keep the majority of the information, all of 
which was seen as important in order to make a decision to participate or not. 
• FG members provided detailed specific feedback on the PIS, consent forms and tri-fold 
leaflet with clear editing, format, layout, and style suggestions, and with the addition of a 
glossary. 
• More information was requested by FG members about provision of information and access 
on emotional support and communicating with family. 
• The FG members supported the current 100,000 Genomes Project option for participants to 
opt-in or opt-out of receiving additional findings results. 
• The FG members had many suggestions on how to approach the transformation of the 
100,000 Genomes Project into part of the routine NHS patient pathway. 
• Some FG members wished for more publicity information to promote the benefits of the 
project. 
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3.2 Health Professional Recruiter Survey  
 
The response rate for the survey was 36% (58/161). The denominator was calculated by asking the 
key contact within each GMC how many health professionals were active during the snap-shot 
period. 
There were some differences between responses from recruiters for rare disease and for cancer. 
Therefore results are presented as responses by rare disease (RD) recruiters first followed by cancer 
recruiters second. The cancer results are highlighted in bold. 
Nearly all GMCs (92.3%, 12/13) participated. The response rate varied between centres, ranging 
from 21 to 100% (median = 29%). The active number of health professionals per centre ranged 
between 3 and 29 (median = 4). Recruiting groups included; Nurses 36.2% (21/58), Doctors 22.4% 
(13/58), Genetic Counsellors 8.6% (5/58), and the ‘Other’ category i.e. those who did not identify 
with one of these groupings above, 32.8% (19/58). 13 of these ‘Other’ respondents stated their job 
titles, which were wide ranging and included; clinical genomic practitioner, clinical trials assistant, 
programme manager, project manager, project co-ordinator, research assistant, research associate, 
research technician. Almost a third of recruiters (32.8%) did not self-identify themselves as a nurse, 
doctor or genetic counsellor. Clinical specialties were wide ranging. The main group was 
genetics/genomics but others were; oncology, urology, cardiac, neuro-genetic, paediatrics and 
perioperative adult nursing (missing 22).  
Two participants (ID numbers 55 & 71) were then excluded from the remaining data analysis 
because they did not complete the remainder of the survey questions, resulting in a data-set 
consisting of 56 participants (N=56). 
Twelve recruiters, 21.4% (12/56), only recruited cancer participants, and 40 recruiters, 71.4% 
(40/56), only recruited rare disease participants. Four recruiters recruited participants for both arms 
of the project, 7.1% (4/56).  Therefore we had N = 60 question set responses, 73.3% (44/60) rare 
disease responses and 26.7% (16/60) cancer responses. 
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Q6, Q7   – Relate to the 100,000 Genomes Project participant information sheet (PIS) 
Q8   – Relates to specific open text feedback on a variety of consent materials 
Q9   – Relates to the 100,000 Genomes Project consent form 
Q10-Q16  – Relate to an 8 week recruitment period February and March 2016 
Q18   – Relates to support for recruiting staff 
Rare Disease and Cancer Recruiters 
The results are presented as responses by rare disease (RD) recruiters first followed by cancer 
recruiters second. The cancer results are highlighted in bold.  
 
This question sought feedback on the participant information sheet in three specific areas – length, 
scientific terms and words, and amount of information. There was general support from the rare 
disease recruiters that the material was ‘about right’ in terms of scientific terms and words (78.1%, 
32/41) and the amount of information (58.5%, 24/41) it contained. However the majority (53.7%) 
thought it was overall ‘too long’.  Also 22% (9/41) felt it was ‘too complicated’ in terms of scientific 
terms and words, with 39% (16/41) stating they felt the amount of information was ‘too much’. 
Nearly all cancer recruiters felt was ‘too long’ (92.3%, 12/13), with a similar proportion to the rare 
disease recruiters saying it was ‘about right’ for scientific terms and words (76.9%, 10/13), and far 
more cancer recruiters felt it contained ‘too much’ information (92.3%, 12/13). 
Recruiters felt that some changes were needed, as reflected by the response of ‘maybe’ or ‘yes’ in 
relation to flow of sections (45%, 18/40: 38.5%, 5/13), consistency of use of scientific terms and 
words (41.5%, 17/41: 30.8%, 4/13), and consistency of use of project terminology (52.5%, 21/40: 
77%, 10/13). 
 
Summary data for all the open text questions is provided at the end of this section. The submitted 
comments have been provided to Genomics England to help inform the re-development of the 
consent materials. 
Q1. Which GMC are you part of? Q2. Please state your Health Professional Group.  
Q3. What is your clinical specialty? Q4. How many health professionals recruit in your GMC?  
Q5. In which section of the project have you recruited participants? 
Q6. We would be interested in your views about the participant information sheet in its ability 
to help the participant make an informed choice about taking part in the project (n = RD44, C16) 
 
Q7a. Do you as a health professional providing consent think any further changes to the rare 
disease participant information sheet are required in the following three specific areas?  
(These specific areas have been highlighted in previous feedback) (n = RD44, C16). 
Q7b. Please use this box to write any suggestions on ways to improve the participant 
information sheet in these specific areas. 
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The submitted comments have been provided to Genomics England to help inform the re-
development of the consent materials. 
The following sections of the consent form were reported by more than 50% of recruiters to have 
caused participants difficulty ‘sometimes’, ‘often’ or ‘very often’.  
Taking part (53.9%, 7/13) 
Samples (50%, 20/40: 69.2%, 9/13) 
Access to my data and confidentiality (77.5%, 31/40: 76.9%, 10/13) 
Results (72.5%, 29/40: 76.9%, 10/13) 
 
 
 
Of the 52 recruiters active during February and March, 36 completed the rare disease question set 
only, 12 completed the cancer question set only, and 4 completed both question sets, giving a total 
of 56 possible responses (n = 56, RD, 40 C, 16). Recruiters were asked to provide a best estimate for 
numbers of participants recruited during an 8 week period around February and March 2016. They 
were not asked to keep a log of recruitment so response is based on recall. 
There was wide variation in the numbers of people recruited by each health professional. 753 rare 
disease and 98 cancer participants were reported to have been recruited by 48 respondents (8 
responses missing). Respondents mainly reported recruiting ‘10 patients or less’ (40%, 16/40: 69.2%, 
9/13). Approximately a quarter of respondents (25%, 10/40: 23.1%, 3/13) recruited ‘between 11 and 
25’ and the remainder (35%, 14/40: 7.7%, 1/13) ‘26 and over’ (response n = RD40:C16). 
 
 
Q11 (n = RD 753, C98) 
Totals  
   n = 851 
 
 
Qr11a 
1 Appt. 
Qc11a 
1 Appt. 
Qr11b 
2 Appt. 
Qc11b  
2 Appt. 
Qr11c 
3 Appt. 
Qc11c 
3 Appt. 
 n % n % n % n % n %   n % 
Participants consented 
 
676 89.8 70 71.4 63 
 
8.3 
 
18 18.4 14 
 
1.9 
 
10 10.2 
Q8. We are interested in your suggestions on ways we could improve any element of the rare 
disease consent materials * select from a drop down list of all information sheets and forms.  
Q9. We are interested in your perception of how often your participants have experienced 
difficulty in understanding each section of the participant consent form (n = RD44, C16) 
Q10, 11, 12, 13 and 15 relate to active recruitment during an 8 week period  
(February and March 2016). 
Q10. During February and March how many participants have you recruited?  
i.e. been the health professional who countersigned their consent form? (RD40, C16) 
Q11. Considering these participants. Please indicate how many face to face or telephone 
appointments they had with YOU prior to signing the consent form. 
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* The dataset contained one rare disease recruiter who reported consenting 110 participants all who took one 
appointment. When removed adjusted percentages are 88% (1 appt), 9.8* (2 appt) and 2.2% (3 appt). (n = 643) 
The vast majority, 89.8% (676/753) of rare disease and 71.4% (70/98) of cancer consents took place 
during one appointment. However 10.2% (77/753) of rare disease and 28.6% (38/98) of cancer 
consents took two or more appointments. 
 
 
Totals 
RD 813 + 
RD 703 * 
C113 
Q12a 
<30 mins 
Q12a 
<30 mins 
Q12b 
30min-1h 
Q12b 
30min-1h 
Q12c 
1-2h 
Q12c 
1-2h 
Q12d 
>2 h 
Q12d 
>2 h 
 n % n % n % n % n % n % n % n % 
Pt’s 246 
136 
30.3 
19.3* 
51 45.1 435 
435 
53.5 
61.9* 
50 44.2 122 
122 
15 
17.4* 
12 10.6 10 
10 
1.2 
1.4* 
0 0 
+ Total participants consented increases here from the number stated in Q11 due to some recruiters completing Q12 who 
had not completed Q11. 
* The data-set contained one rare disease recruiter who reported consenting 110 participants all <30 mins. When removed 
this does affect the proportions and the adjusted percentages are presented in the table above and text below and are 
noted by * (n = 703) 
 
Recruiters reported that between a half and two-thirds of rare disease and cancer participants took 
‘30 minutes to one hour’  (61.9%* 435/703), 44.2% (50/113) to consent. About a quarter of rare 
disease participants took ‘less than 30 minutes’ (*19.4% 136/703), compared to 45.1% for cancer 
participants.  There was evidence of longer consent times; 18.8%* of rare disease participants took 
greater than one hour, and 10.6% for cancer participants. 
 
 
Consent 
occurred 
during 
routine 
clinical care 
Less than 25% 26-49% 50-74% 75%-100% missing total 
 n % n % n % n % n % n % n % n % n n n n 
Respondents 29 78.4 0 0  3 8.1 0 0 1 2.7 1  7.7 4  10.8 12 92.3 3 3 40 16 
 
The most common scenario for rare disease participants, occurring three-quarters of the time 
(78.4%, 29/37), was that ‘less than 25%’ of the consent contacts occurred within the participant’s 
routine clinical care appointment.  In contrast nearly all cancer participants (92.3%, 12/13) were 
‘consented during normal clinical care’.   
Q12. Considering these participants. Please indicate the total time you spent in face to face or 
telephone discussion with the participant. 
Q13. Considering these participants. What proportion of these appointments took place during 
the participant’s routine care clinical appointment? (n = RD44, C16) 
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From an option list of seven possible specific need areas highlighted by previous research, 50% or 
more of recruiters reported that for rare disease and cancer participants (in bold) the following 
areas ‘sometimes’, ‘often’ or ‘very often’ caused difficulties for participants: 
• ‘Extra explanation needed to understand the participant information sheet & consent form’ 
(85.4%) (100%) 
• ‘Low levels of literacy’ (50%) (33.3%) 
• ‘Visual impairment’ (35.9%) (50%) 
• ‘Increased levels of anxiety related to current health situation’ (56.4%) (100%) 
Issues are similar to those stated by rare disease recruiters, but cancer recruiters suggest specific 
needs relating to participants’ anxiety related to their current health situation, and less need relating 
to low levels of literacy. 
 
58.3% (21/36) of rare disease recruiters stated that ‘no-one had declined the project’ (4 missing). 
This is in contrast to 16.7% (2/12) cancer recruiters who said that ‘no-one had declined the project’ 
(4 missing). A further 38.9% (14/36) of rare disease recruiters had ‘between 1 and 10 decliners’, the 
remaining (2.8%) had ‘20 to 31 decliners’ and had recruited 30 in total. A rare disease recruiter who 
consented 110 participants reported ‘no decliners’.  The majority of cancer recruiters, 83.3% (10/12), 
stated that ‘between 1 and 10’ had declined (4 missing).  
 
Summary data for all the open text questions is provided at the end of this section. The submitted 
comments have been provided to Genomics England to help inform the re-development of the 
consent materials. 
Of the rare disease recruiters, 25% (10/40) felt ‘very confident’, 62.5% (25/40) felt ‘confident’, and 
12.5% (5/40) felt ‘somewhat confident’. None selected ‘not confident’ or ‘prefer not to say’ (4 
missing).   Of the cancer recruiters, 16.7% (2/12) felt ‘very confident’, 66.7% (8/12) felt ‘confident’, 
and 16.7% (2/12) felt ‘somewhat confident’ (4 missing). 
 
 
Q14. Within the last 2 months how often have your participants presented with 
specific needs which you needed to address as the consenting health professional during the 
consent process? (n = RD44, C16) 
Q15. During February and March, approximately how many patients have you met who 
declined participation? (n = RD40, C16) 
Q16. What factors might have influenced these participants to decline? 
Q17. How confident do you feel in delivering a quality consent process to potential participants 
of the 100,000 Genomes Project? (RD44, C16) 
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Summary data for all the open text questions is provided at the end of this section. The submitted 
comments have been provided to Genomics England to help inform the re-development of the 
consent materials. 
Open text summary – Rare Disease Recruiters (Questions rQ7, rQ8, rQ16, rQ18).  
There were alternative perspectives present; comments were received for the materials both to be 
more concise and more detailed (sometimes asked for by the same recruiters).  
• Where materials could be more concise 
o Where individual points made are ‘wordy’ or could be represented by bullet points 
o Where it is repetitious e.g. between key points in ‘blue box’ and long text 
o Where it seems superfluous e.g. text on Mental Capacity Act 
• Where more information may be needed, on particular areas that patients are concerned 
about 
o What are the possible ‘additional findings’?  
o On specific additional tests 
o On ‘carrier status’ 
o When main findings can be expected 
• Applicability to particular patient needs 
o Patients physically unable to sign a consent form 
o Those with poor educational levels/literacy (suggestion is to use the 11-15 booklet) 
o Preparedness to read a long document and really engage with it “people want to be 
told where to sign!” 
o Those better suited to images/audio/HCP reading information to them (produce 
audio?) 
o Children (who might not consider themselves ‘ill’) 
• Physical/online materials 
o Large number of items to initial (one signature on each page is enough?) 
o Consent form too long and repeats PIS 
o Too many bits of paper 
o IT can be very clunky (e.g. the EDCT, uploading consent materials) 
Family dynamics engaging with materials 
• Partners of patients may feel left out as they can’t be ‘participants’, especially if they want to 
have children 
• More emphasis needed on where are ethical concerns regarding other people/family; can 
staff support this? Sometimes people decline as they worry about impact on family 
• Sometimes the patient wants to take part but other family members do not; siblings refuse 
having blood taken 
Consent and Participation Process 
• Lack of time (needing to leave at certain time), clinics too busy to embed recruitment 
• Participants often need to come back just for recruitment (HCPs try to combine these with 
clinical review) 
Q18. Are there any ways in which Genomics England could support you as a health professional 
more with the delivery of a quality consent process? 
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• Comes at a bad time when people cannot cope with thinking about another complex issue 
• Can create anxiety in some 
• Need for a blood test (esp. those are afraid of needles/children) 
• Some people just lack understanding/interest 
• Helpful to contact patient in advance and gauge interest 
Particular concerns with the project for patients 
• Data security who owns data/data storage 
• Related issues of insurance, reluctance especially for commercial companies to have data 
What would be helpful to the consenting process 
• Additional information/different formats 
o Information on audio 
o Information on DVD 
o Images to support the information  
o Shorter booklet with more additional materials 
 
• Changes to the materials as outlined above e.g. simpler, shorter, fewer ‘bits of paper’, use of 
images and video 
• Promotional material to display in clinics; wider publicity about the project 
• More training, in particular 
o Briefing on additional genetic conditions that may be found/on carrier status 
o Top-up training as it makes a lot more sense having had the experience 
o Having done the genetics quiz should be mandatory as part of consent training 
o Face-to-face training sessions 
 
• Less targets and pressure especially for small teams 
• Some argued for nominated, specially trained staff to do the recruiting 
Responses from cancer recruiters. Comments were very similar to the rare disease recruiters’ 
responses but a few were unique to patients with cancer: 
• Issues around explaining ‘reproductive findings’ 
• Huge amount of information received after diagnosis of cancer, or weeks before a major 
operation, this comes at a bad time 
• Sometimes patients are at the clinic just for surgery 
• Need for a short genomic counselling course focusing on feelings/reactions 
• Possibility to consent to having a tumour sample stored and rethink later? 
 
Summary  
 
In summary, the health professional survey covered Genomic Medicine Centres with a varied 
number of recruiters from a variety of professional backgrounds. A limitation is that based on the 
estimated numbers of recruiters who were sent the survey, our response rate is 36% (58/161). It is 
possible that some recruiters did not know about or receive the email survey link.  Two reminders 
were sent by the local contact (usually the programme lead) and reassurances obtained that all 
health professionals had been given the opportunity to respond. It is possible that those recruiters 
who chose not to respond had differing demographics or views from those presented here. This low 
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response rate, although comparable with on-line surveys of NHS staff, means that responder bias 
has to be considered when inferring outcomes from the survey data.  
Many of the health professionals who responded provided detailed suggestions on how Genomics 
England could change the current consent process or materials and these have been provided to 
Genomics England to help with the development of the consent materials. Some health 
professionals stated the wish for further training and on-going development and had suggestions on 
how this could be achieved.  
• 58 recruiters out of the 161 who were active during the period responded, providing their 
experiences of recruiting participants (response rate 36.5%). 
• The additional consent materials were welcomed (especially the introduction leaflet) and 
were seen as useful in informing participants. Recruiters asked for more promotional 
materials to raise awareness. 
• Recruiters commented that the consent form was too long and repeated information in the 
participant information sheet; and questions were raised as to why multiple signatures were 
required and not just one. 
• Many suggestions were made as to how the materials/documentation could be improved 
e.g. consistency of terminology, less dense, more pictures. Suggested changes to the 
materials e.g. simpler, shorter, fewer ‘bits of paper’, use of images and video. 
• The importance of the health professional recruiter in the consent process was stressed with 
the written material needing verbal explanation of genetic concepts and clarification during 
the majority of consent interviews. 
• 50% or more recruiters stated that they perceived participants experienced difficulty in 
understanding the following sections of the consent form; ‘taking part’, ‘samples’, ‘access to 
data and confidentiality’, and ‘results’. 
• There was concern from the recruiters about the length of time taken to consent (69.7% of 
rare disease patients took ‘more than 30 minutes’, in contrast to 54.9% of cancer 
participants) and also the timing of the discussion especially for anxious newly diagnosed 
cancer patients. 
• Rare disease recruitment seemed to be occurring in special clinics. 78.4% of rare disease 
participants were recruited ‘not during their routine care appointment’ in contrast to 92.3% 
of cancer participants who were recruited ‘during their routine care appointment’. 
• 87.5% of rare disease recruiters and 83.4% of cancer recruiters were ‘confident’ or ‘very 
confident’ in delivering a quality consent process. 
• Suggestions were made to Genomics England regarding how they could support the 
recruiting staff to deliver the consent process e.g. training updates (face to face), 
information on timescale for results, training on additional findings, carrier status, patient 
emotional response, improve IT project infrastructure, advice on how to respond to patient 
queries (once in the project), introducing dedicated recruitment staff as clinical staff may not 
have the time. 
 
3.3 Participant Survey  
Overview 
12 out of 13 GMCs participated in the survey. Responses per GMC ranged from 2 to 49.  As there is 
large variation in 100,000 Genomes Project recruitment between GMC sites this is not unexpected. 
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No individual GMC contributed more than 26% of the returns, thereby the results represent a range 
of GMC activity during the snapshot 8 week period. 
174 responses were received, 87.8% (153/174) rare disease and 12.2% (21/174) cancer from a total 
of 1196 participants recruited (1045 rare disease and 151 cancer), giving a response rate for rare 
disease participants 14.6% (153/1045) and cancer participants of 13.9% (21/151), and an overall 
response rate for the participant survey of 14.6%. The denominator for response rate is based on 
Genomics England weekly reporting figures for the 8 week period when cards were being handed 
out. 
Two rare disease postcards were completed by children and their results are not included in the 
main analysis as research ethics permissions did not cover seeking children’s views.  Notably, the 
open text comment on the card was – “why no option for children’s views?” 
Comparing the responses given by the cancer participants with the rare disease participants there is 
unlikely to be any statistically significant differences between the rare disease and cancer participant 
response groups. Therefore the results below are presented together for the two groups.  
Rare Disease & Cancer (n = 172) 
Demographics 
Nine participants responded using the individual password controlled on-line option and 163 by 
returning a response postcard. Forty percent of respondents were male (64/160) and 60% female 
(96/160), 12 missing. The majority 75.5% (129/171) were between the ages of 25-64, with 2.9% 
(5/171) between the ages of 16 and 24, and 21.6% (37/171) 65 or over, 1 missing. Reponses were 
received mainly from affected adult patients with a rare disease 31% (52/198) and from the 
unaffected parents of a participating child 31% (52/168) and also from adult patients with cancer 
11.3% (19/168), 4 missing. All participation categories were represented. 
 
The majority of 100,000 Genomes Project participants had seen or viewed the Participant (92.5%) or 
Consultee (32.2%) Information Sheet & consent form. The Introductory Booklet was read or viewed 
by 36%. However the videos and animations (5.6%) and flip chart (7.5%) had not been read or 
viewed by many participants, 11 missing responses for this question. 
 
 
Q2 Poor Satisfactory Good Excellent  
How do you rate the… n % n % n % n % missing total 
..overall satisfaction with your consent 
experience 
0 0 3 1.7 35 20.3 134 77.9 0 172 
..written information given about the 
project 
1 0.6 9 5.3 51 30.2 108 63.9 3 172 
..verbal information given about the 
project 
1 0.6 1 0.6 35 21.0 130 77.8 5 172 
..care and attention you have received 0 0 0 0 27 16.1 141 83.9 4 172 
Q1. Please tick which of the following materials you read or viewed prior to consenting to 
participation in the 100,000 Genomes Project. 
Q2. How do you rate the …….. 
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The majority 98.3% (169/172) of participants rated their overall satisfaction with the consent 
experience as ‘good’ or ‘excellent’.  They rated elements of the consent experience as ‘good’ or 
‘excellent’ for written 94.1% (159/169), verbal 98.8% (165/167) and overall care 100% (168/168). 
They were least satisfied with the written information. 
Chi-square analysis was performed to detect if overall satisfaction rating was associated with the 
following variables; type of disease, patient category, gender or age group. No statistically significant 
associations were found apart from that older age groups are more likely to read the PIS in more 
detail than younger age groups (p < 0.02), and men are more likely to rate satisfaction with verbal 
information highly than women (p < 0.02). 
The majority, 66.1% (113/171) ‘read all the sheet in detail’. However 32.2 % (55/171) ‘scanned but 
did not read in detail’, and 1.8% (3/171) ‘did not read any’, 1 missing (n = 172).  
Participants were asked to feedback on three areas. There was overwhelming support that the PIS 
was ‘about right’ as regards length (88.7% 149/168), scientific terms and words 96.4% (163/169), 
and amount of information (92.9%, 157/169). 10.1% (17/168) felt it was ‘too long’ and 4.7% 8/169 
felt it contained ‘too much’ information. 
 
 
Q5 Less Right More Missing Total 
 n % n % n %   
Use and storage of samples       6 3.6 151 90.4 10 6.0 5 172 
Results related to main condition 5 3.1 121 74.2 37 22.7 9 172 
Additional results unrelated to main condition 7 4.3 130 79.8 26 16.0 9 172 
 
Approximately three-quarters of participants felt that the amount of information included in the PIS 
was ‘right’. However 22.7% (37/163) of participants would like ‘more information’ about results 
related to their main condition and 16% (26/163) ‘more information’ about additional results.  
Nearly all participants, 99.4% (165/166), answered ‘yes’ to this question. 
 
All participants answered this question and views were divided. 26.2% (45/172) would have been 
satisfied ‘with a shorter information sheet if the complete text was on-line’, 36.6% (63/172) would 
not. There were 36.6% (63/172) who were undecided and gave a ’maybe’ response. 
 
Q3. How much of the participant information or consultee information sheet did you read? 
Q4. What did you think about the participant or consultee information sheet you read? 
Q5. In the information sheet would you have liked more or less detail to be included about? 
Q6. Did you feel you were given enough time to understand all the information prior to signing 
the consent form? 
Q7. Would you have been satisfied with a shortened information sheet as the more complete 
text is available on line? 
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This was the only opportunity for participants to write feedback on the postcard. The area for 
response was however limited to one line only, which may have deterred longer responses. There 
were 113 comments, 91.1% (103/113) consisted of ‘no’, ‘nope’, ‘none’. The others are presented 
below. n = 113 
Text n 
Deciding whether to ask for carrier information to be given to me 1 
I particularly appreciated the lady ……explaining to my young daughter about extracting DNA and 
blood cells 
1 
Poor wording in some areas which caused confusion 1 
Some 2 
Some issues about consent are quite confusing 1 
Too much information to read through, needs to be quicker and easier to read, appreciate it is 
complex project 
1 
Unfortunately process takes very long time 1 
Was a bit long worded, could be more concise 1 
Yes, the question regarding "do you want to know about other results...if the project discovers I might 
be at higher risk of developing another disease" it’s a very big Q 
1 
 
The following suggestions/comments were made. 
A film showing more information showing what happens with your samples 
Having a CD/DVD to watch may have helped. 
I would like to have seen a film showing the process of what happens from the time your blood is taken 
No/None (2) 
Whole process & discussion were clear & concise. Many thanks!! 
 
Summary 
The overall response rate for the participant survey was 14.6% (174/1196). We received assurances 
from the key contacts at each GMC of the date when the postcards were available to be handed out 
to potential participants.  
Response rates can be influenced by many things such as survey distribution, perceived benefits, and 
demographics (Aldridge Alan 2001). The NHS England Friends and Family test is similar in design to 
the feedback postcard used in this study. Estimates show that between 18-34% of eligible patients 
complete the Friends and Family survey (NHS England 2014). This shows that the response rate for 
the participants in this study is below what might be expected.  
Q8. Were there any bits (document or process)  
of the consent experience that were difficult or confusing? 
Q12. Are there any ways we could improve the consent experience?  
(Only asked on the on-line option to complete the survey) 
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Response bias also needs to be carefully considered when interpreting the results of the participant 
survey. It is important not to over-generalise the results considering that they are provided by only 
14.6% of those who were consented for the 100,000 Genomes Project during the snap-shot 2 month 
period. For instance, measures of satisfaction have a common-sense and political appeal, but they 
are the measures that experts, including experts in quality improvement, consider the least useful 
on their own for improving patient experiences locally (Mazor KM, Clauser BE et al. 2002, The Health 
Foundation 2013). Some key findings are outlined below but should be used with caution as 
participants who did not complete the survey may hold differing views. 
174 out of the 1,196 participants (of the 100,000 Genomes Project) who consented during the 
period completed feedback postcards: 
• 100% of participants rated their satisfaction with the care and attention they received as 
‘good’ or ‘excellent’. 
• 98.3% of participants rated their overall satisfaction with their consent experience as ‘good’ 
or ‘excellent’. 
• 94.1% of participants rated their satisfaction with the written materials as ‘good’ or 
‘excellent’. 
• However 32.2% ‘only scanned and did not read the PIS in detail’, and 1.8% ‘did not read it at 
all’. 
• The vast majority 88.7-96.4% felt the length (89%), scientific terms (96%) and amount of 
information (93%) in the participant information sheet was ‘about right’. The main criticism 
being that 10.1% felt it was ‘too long’. This was in contrast with health professional 
recruiters where 92.3% thought it was ‘too long’. 
 
4 Synthesis of Activities 
Synthesis methods 
 
Up to this point the results from the three stakeholder groups had been analysed independently of 
each other adhering to the measures of quality and validity appropriate for methodology used 
(Qualitative and Quantitative). This chapter reports the Synthesis stage of the analysis, following the 
parallel mixed designs framework (Teddlie 2009), the final stage is a meta-inference of the results 
from all three activities. The following iterative process was undertaken.  
• During a project team meeting the data from each of the three activities was discussed and 
similarities and differences between stakeholder groups were noted. Evidence from each 
stakeholder group was collated across the 10 original pre-defined areas of focus. 
• The evidence was then re-read and grouped into facilitators (things which stakeholders 
reported were going well with the consent process) and barriers (things they thought could 
be improved). It was collated under the original pre-determined 10 key areas of focus for the 
evaluation. When examining the best presentation for the evidence obtained, the original 10 
pre-determined areas of focus were collapsed down to five and then presented as four 
synthesis tables  
• A synthesis table was then produced for each of the four areas of focus and included 
suggestions made by each stakeholder group are presented as a third column in the tables. 
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• The Simplemind visual network app. was used to view the data and to assist with this 
process where evidence was tracked back to the stakeholder group using icons.  
Focus Groups = People   
Health Professional Recruiters = Mortar Board   
Participants = Rosette   
 
• The tables and the Simplemind diagrams were then iteratively reviewed and draft 
recommendations made for presentation to Genomics England. The evidence supporting the 
recommendations is tracked back to the underpinning evidence by cross-reference to the 
synthesis tables (recommendation numbers placed alongside evidence in the synthesis 
tables). 
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Visual Mapping 
Figure 10 Example of visual mapping which helped create the synthesis tables 
Focus Group Comment 
Health Professional Recruiter Comment 
100,000 Genomes Project Participant 
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Synthesis Tables 
 
Table 1 Pre-determined areas of focus (1, 2, 3) – Logical flow (1), complexity of consent materials (2), use of scientific terminology (3) 
 
 
 
 
 Facilitators 
(things going well) 
Barriers 
(things to consider changing) 
Suggestions to consider 
 
 
(FG) There was support for the recent changes and 
additions (video/information leaflet) and for the key point 
boxes, colours and formatting. (1,3, 5) 
 
(HP) About half felt the RD PIS for RD was ‘about right’ in 
terms of length, scientific terms and amount of 
information. (3) 
 
(P) The vast majority of participants (88-96%) felt the PIS 
was ‘about right’ in terms of length, scientific terms and 
amount of information. (1,2,3) 
 
(P) 94% rated the written materials as ‘good’ or ‘excellent’. 
(1,2,3) 
 
(P) 91% participants (n = 113) stated they found no bits of 
the consent experience difficult or confusing. (1,2,8) 
(FG) The majority opinion was that they would not suggest reducing 
information but that currently the PIS and Consent Form are still ‘too wordy, 
dense, do not meet 9-13 year old literacy levels and there are gaps and 
inconsistencies in use of scientific terminology. (3,9,11,12,14) 
 
(FG) Some members did not feel the PIS ‘sold the project well’ in terms of 
personal patient and family benefits (RD) and value to the NHS in terms of 
prevention and treatment of disease in the future. (20) 
 
(FG) The focus groups were critical of the three-fold DL leaflet ‘The 100,000 
Genomes Project’ as it was unclear who the audience for this was and many 
terms not explained. (16) 
 
(HP) 53.7% felt the RD PIS was ‘too long’, 22% ‘too complicated and 39% 
‘contained too much information’. 
(HP) 92.3% recruiting cancer participants felt PIS was ’too long’ and 
contained’ too much information’. (9,11,12,13,21) 
 
(HP) 50% or more of the participants they recruited had had ‘sometimes’ 
‘often’ or ‘very often’ had difficulty with consent form sections – samples, 
access to data and results sections. (6,8,14,15, ,17,,18) 
 
(P) 32% of participants only scanned but did not read in detail the 
PIS.(9,12,17,22) 
 
(P) Only 7.5% viewed the flip chart and 5.6% the videos/animations. (13) 
 
Aim to increase the number of participants who actually read and engage 
with the PIS; 
 
• having a ‘glossary of terms’ document 
• having more visual images/pictures/diagrams in PIS 
• A new ‘easy read’ version or the option of being able to use the 
‘young persons’ leaflet for adults if low levels of literacy 
• An ‘easy-read’ version for participants with low levels of 
literacy, learning difficulties 
• re-write to meet 9-13 literacy standards 
• reduce repetition between PIS and consent form and between 
key information boxes and text 
• add section on emotional concerns and where emotional 
support (psycho/social and family communication) may be 
obtained from 
• Non-English and low vision versions 
• shorter PIS for cancer participants 
• Consider why the need to include seemingly lengthy text on 
Mental Capacity Act 
• Produce an audio version of the PIS, more suited for people 
who do not process text information well 
• To include the name of next of kin/family member to whom 
results to be given on cancer consent form 
• Re-design of the one-page tri-fold leaflet if intended for patient 
use.  
 
. 
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Table 2 Pre-determined areas of focus (4, 7) - Issues related to main and additional findings, including opt in/opt out (4) and seeking broad vs. specific consent in relation to additional findings (7) 
Facilitators 
(things going well) 
Barriers 
(things to consider changing) 
Suggestions to consider  
 
(FG) Strong preference to keep the option of testing 
for additional findings and the ability to opt-in and 
opt-out (dynamic consent). (7) 
 
(P) 74% of participants felt the information in the PIS 
on main condition and 80% on additional findings 
was ‘about right’. (1,2,3)  
 
(FG) However there was uncertainty about where participants would go for 
further information about the conditions currently tested for, support in 
making the opt-in/out-out decision and guidance on how to talk to family 
members about topics. (15,17,,18) 
 
(FG) A list and more information, i.e. links, available to participants on the 
conditions tested for now and updated as testing changes in the future. 
(15,13,18) 
 
(FG) A realistic indication to participants when main finding results might be 
expected. (15,13,18) 
 
(HP) 33% of RD HP and 23% of cancer HP recruiters stated that participants 
‘often’ or ‘very often’ had difficulty with the results section of the consent 
form. (15,17,18) 
 
(HP) Some HP stated that patient confusion or concern regarding results 
(both main findings and additional findings) were the reason why some 
decided to decline participation. (15,17,18)  
 
(HP) Some HP stated that patient concern over possible or unknown impact 
of the results on family members had been a reason for patients to decline 
participation.(17,18) 
 
(P) 23% of participants would like more information on the PIS about the 
main condition. (15,18) 
 
(P) 16% would like more information on the PIS on additional findings. 
(15,18) 
• Signposting participants as to where they may get an 
opt-in/opt-out form 
• Provision of a pre-paid return envelope where they 
could send back opt-in opt-out forms after their initial 
decision 
• Patient accessible on-line list of currently looked for and 
reported additional findings on the Genomics England 
website with links to trusted patient focused 
information sources. 
• More information on the currently tested for conditions 
and implications for family members. 
• More health professional training on how to explain 
these conditions, especially carrier conditions or where 
to signpost patients for more information. 
• More training for health professionals in describing what 
the opt-in choice will mean for participants 
• Information available as to when realistically 
participants are likely to receive results related to main 
findings or additional findings 
• To provide a number/estimate of the chance that a 
participant might receive an additional finding 
• More information in the PIS about additional findings 
and process of receiving main results 
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Table 3 Pre–determined areas of focus (5) Data security, privacy and sharing (5) 
Facilitators 
(things going well) 
Barriers 
(things to consider changing) 
Suggestions to consider  
 
(P) 90% of participants felt that the amount of 
information in the PIS on use and storage of samples was 
‘about right’.  
 
 
(FG) There was lack of clarity of who gains access to data and at 
what time-points. The data-sharing language is unclear i.e. 
anonymised vs. pseudo-anonymised, de-identified. (14) 
 
(FG) Some members raised concern about disclosure of 
personal information to insurance companies. (13,14,) 
 
(FG) Some members had concerns regarding the influence 
private genomic companies has on the NHS. (13,14) 
 
(FG) Some felt there needed to be greater clarity in the 
participant materials that there is a money making element of 
this, with private companies accessing data – for the benefit of 
the NHS. (13,14) 
 
(HP) Recruiters stated that two thirds of participants 
‘sometimes’, ‘often’ or ‘very often’ experienced difficulty with 
the RD and Cancer consent form section ‘access to my data and 
confidentiality’. (9,11,13,14) 
 
(HP) Some stated that patients may have declined participation 
due to concerns related to data security, ownership and 
reluctance for commercial companies to have the data. (13,14) 
 
 
 
• Clarify the data-flow, who has what access to what portion 
of data and when e.g. specialist, GP, NHS England, 
researcher, private company 
• Be clear at what points it is considered anonymised or 
pseudo-anonymised, de-identified, and use examples of 
‘real life’ scenarios/requests to explain access rights 
• Consider a video showing ‘what happens to my sample 
and data after I donate it’ 
• Consider additional training and materials to support the 
health professional recruiters in this area 
 
. 
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Table 4 Pre –determined areas of focus (6, 8, 9, 10, 11) - Nature and timing of approach (6), time taken to consent (8), consent interview (9), flexibility and pre-determined pathway (10) and 
transformation/legacy of project (11) 
Facilitators 
(things going well) 
Barriers 
(things to consider changing) 
Suggestions to consider  
(FG) Members who were participants have had 
good experiences of the consent process. 
Describing various approaches in operation 
face to face in clinic, by email, by telephone, 
open day or a combination. (1,3,5,8)  
 
(FG) Members felt it was important to give the 
HP adequate time to consent families and 
additional time for those needing extra 
support (e.g. learning disabilities, new cancer 
diagnosis). (8,18,23) 
 
(HP) 90% of rare disease consents took place at 
one appointment vs. 71% for cancer 
participants. The rare disease appointments 
nearly all took place OUTSIDE of routine clinical 
care, whereby three-quarters of cancer 
consent were WITHIN their routine care 
appointments. (18,22,23) 
 
(HP) 54% RD and 45% of cancer consents took 
less than 30 minutes. (18,23) 
 
(HP) There were a diverse range of consenting 
professionals with 36% nurses, 22% doctors, 
9% genetic counsellors and 33% others (who 
did not identify with groups above), these 
consisted of clinical trials assistants, research 
assistants and research technicians. (19,20) 
 
(HP) Number of participants consented per 
recruiter during an 8 week period varied 
(FG) Some members were critical about the consent process; too much 
administration and disorganisation and not enough collaboration. (18,19,20) 
 
(FG) There was concern raised about NHS England’s ability to provide appropriate 
feedback and support to participants. (15,22) 
 
(FG) there were concerns about the logistics of the project, i.e. continuity after the 
pilot, availability of long-term staff were discussed in another group. The ability of 
healthcare teams to pick up that work after the project ends and feedback of 
information was questioned by participants. (8,17,22) 
 
• Consider mechanisms to support the time 
required for participants to learn about the 
project, assimilate the information and make an 
informed decision to participate. 
• Importance of interaction and support from HPs. 
• Provide patients with information about social 
and psychological support organisations/groups 
• All participant materials available on-line and 
easily found by patients 
• Balance between meeting recruitment targets 
and providing time for consent process 
• Clarity in what support mechanisms will be in 
place for families already in the project when 
recruitment closes 
• Given the diverse range and backgrounds of 
people taking consent some assessment of 
capability of consent might be considered – 
formal assessment, suggestions included making 
a pass level for the genetics quiz or GCP training 
mandatory for consenting staff 
• The usual pathway for rare disease consenting 
seems that the patient is invited for a ‘consent 
taking’ appointment outside of routine clinical 
care and this differs from the cancer participants 
– Perhaps need to consider differing support and 
consent pathways for the two groups 
• Participants overwhelmingly were very satisfied 
with the process overall and only a few 
suggested areas which had been difficult or 
confusing (limitation on postcard methodology) 
 
 
(HP) 70% of RD and 55% of cancer consenting took over 30 minutes to complete. 
(8,17,22) 
 
(HP) 16% of RD consents and 11% of Cancer consents took over 1 hour. (8,17,21,22) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This diversity could also prove a barrier for adequate 
training and updating. 
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Facilitators 
(things going well) 
Barriers 
(things to consider changing) 
Suggestions to consider  
between 1 and 110 (rare diseases) between 1 
and 25. (19,20) 
(HP) 38% GMCs  had 1 to 5 recruiters active, 
26% between 6 and 10, and 36% from GMCs 
with over 10  (13) 
 
(HP) 87% of rare disease and 83% of cancer 
recruiters felt ‘very confident’ or ‘confident’ in 
delivering a quality consent process. (8) 
 
(P) Overall 100% of participants rated the care 
and attention they had received during the 
consent process as good or excellent. Cancer 
participants were less likely to rate excellent 
than RD participants (70% vs.85%). 
(8,18,19,23) 
 
(P) Overall 99% of participants rated verbal 
information about the project as good or 
excellent. (1,8,18) 
 
(P) 98% of participants rated their overall 
satisfaction with the consent experience as 
good or excellent. (1,2,3,8,18) 
 
(P) Of 113 responses to the open question – 
any bits found confusing or difficult – 91.1% 
reported ‘none’ and often added very good 
comments about the role of the HP in the 
process. (1,2,3,8,18,19) 
 
The participants were equally split between 
whether they would want a shortened PIS if 
more information was available on-line – 26% 
‘yes’, 37%, maybe, 37% ‘no’. (4) 
 
(HP) Comments – clinics too busy to embed recruitment, running out of time, often 
difficult to combine with routine clinical care, some suggested nominated specially 
funded staff for this project. (17,18,,21,22) 
 
(HP) The need to have a blood test vs. saliva and also having to re-schedule to come 
back is a cause for declining participation. (21,22) 
 
(HP) Cancer – recruitment comes at a very difficult time for the patient as they have 
just been told they likely have cancer, very emotional and difficult to consent at this 
time without overburdening the participant. (21,22) 
 
(HP) 13% of rare disease and 17% of cancer recruiters only felt ‘somewhat 
confident’ in their ability to provide a quality consent process. (18,19) 
 
 
• Health professionals were involved in 
summarising and translating/explaining the 
context of the project, definitions and scientific 
concepts to patients – this takes time. 
 
• Health professionals suggested having more 
promotional materials so that they could raise 
the profile of the project locally 
 
• Focus groups felt integration of the project into 
routine NHS care needed much careful thought 
and it would need robust funding and 
sustainability planning. 
 
• Focus groups would like to see regular reporting 
on progress, which is made public and 
transparent, throughout the project’s life, to 
inform the transformability aspects. 
 
Health Professional identified training needs 
 
• Education on conditions on additional findings 
list 
• Short genomics course on 
feelings/reactions/communicating genetic 
information with family 
• Education on carrier testing 
• Support how to discuss with patients how to 
involve their family members 
• Top-up training  
• Provision of list of where families can go for 
psycho/social support for their condition. 
(P) Of the 8.9% of open text responses to ‘were there any difficult elements of the 
process’ – these included process takes a long time, decision making regarding 
additional findings takes a while, too much written information. (15,17,18) 
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Synthesis summary 
Four descriptive categories (meta-inferences) were developed from the synthesis activity. The 
summary needs to be read taking account of the methodological restrictions and strengths of this 
evaluation. The strengths lie in the fact that all GMCs contributed in some way and that views were 
elicited from three stakeholder groups, representing the geographical spread of the project.  Also 
the evaluation was focused on an 8 week period where the consent material or processes did not 
change and where reliable estimates of response rate could be obtained. 
1. “Differing views” - This category describes the finding that there were differing views provided 
across this evaluation. This is to be expected as participants in this evaluation will have differing 
perspectives and experiences which will influence their responses. Of interest were the similarities 
between the health professional recruiters and the non-participant focus group members, who 
tended to be most critical of the consent materials and process. 100,000 Genomes Project 
participants who attended the focus groups and those who completed postcards were 
overwhelmingly supportive of the project and the care they had received.  
2. “Dialogue, Decisions and Dependency” - This category describes the important factors 
highlighted by many respondents in that deciding to take part or not in the 100,000 Genomes 
Project required dialogue between many people - potential participants, their families, the routine 
clinical care team and the consenting staff of the 100,000 Genomes Project. There were many 
examples of different pathways leading to the patient declining or agreeing to participation. 
Throughout this category the major issue of importance was the clarity of consent materials in 
informing and documenting discussions and decisions. The front-line recruiting staff are dependent 
on their GMC for the infrastructure and management as well as to the central 100,000 Genomes 
Project team for central advice and materials. Recruiting staff felt confident in providing a quality 
consent process but also identified areas where they would welcome additional training and 
requested an on-going supportive infra-structure for protected time to take consent and also 
updating.   
3. “Support & Follow up care” - Most stakeholder groups highlighted the importance of providing 
patients/participants with more information regarding support especially with emotional and 
practical issues arising due to being a part of the 100,000 Genomes Project. Areas highlighted were 
‘family communication’ and ‘psychological support’. Issues were mentioned about the need for 
clarity regarding; what happens with data and results after a participant had consented, how to 
manage participants’ expectations and feedback regarding how samples are to be used by 
researchers and private companies. Of importance was clarity for participants regarding the pathway 
by which information (result found or not) will be fed back to them and the timescale for this. 
4. “Improvements” - This category describes the finding that both the recruiters and the focus group 
members felt that the PIS and consent form for both Rare Disease and Cancer participants should be 
improved. Many helpful suggestions were made. The responses from 100,000 Genomes Project 
participants were very satisfied with the consent process and their care and they felt no significant 
changes should be made – but this finding may not be generalisable across all participants due to the 
low response rate (14.6%). Also under this category are improvements which were suggested to the 
timing of the consent discussion, especially for the cancer participants, where scheduling an extra 30 
minute consent discussion at a time when the patient is anxious about diagnosis and treatment is 
proving difficult. Also recruiters commented on the burdensomeness of the Information Technology 
systems for recording consent and sample collection. 
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5 Recommendations 
 
This snap-shot evaluation (mid-way through the 100,000 Genomes Project) showed that there were 
differing opinions both within and between stakeholder groups. This means that when considering 
the development of materials to help facilitate consent, it is important to bear in mind that how they 
are perceived and utilised will differ in relation to context and the individual participant’s 
information needs. 
The results of this evaluation need to be considered alongside on-going and published research as 
well as ongoing policy debate regarding consent for whole genome sequencing. 
There was support for the supplementary materials developed to help with the consent process, 
such as the information leaflet, animations and flip-chart. These were viewed as being useful in 
preparing patients for the consent discussion. Suggestions were provided concerning how to support 
NHS recruiting staff, including on-going training. Overall, staff who completed this survey (who 
represented 36% of active recruiting staff at the time of the evaluation) felt ‘confident’ or ‘very 
confident’ in being able to provide a quality consent experience. Although not necessarily 
representative of all participants, due to the response rate of 14.6%, those 100,000 Genome Project 
participants who returned a feedback postcard (n = 172) were extremely satisfied with the consent 
materials and process they experienced.  Participants in the focus groups were also supportive of the 
information included in the consent material. There were aspects of the consent materials and 
consent process that received positive comment from all stakeholder groups.  
However, evidence of where the materials could be improved was also found. Concern was raised by 
recruiters and focus group members regarding the length and readability of the participant 
information sheets (PIS) and consent forms and they proposed specific changes that could be made. 
These are detailed in the ‘National Service Evaluation Project: Background Document’ which is 
available to Genomics England for review when implementing changes to the consent material or 
process. Half of the recruiters perceived that participants ‘sometimes’, ‘often’ or ‘very often’ 
experienced difficulty with certain sections of the consent forms, especially the sections ‘taking 
part’, ‘samples’, ‘access to my data and confidentiality’, and ‘results’. Approximately half of the 
recruiters reported that participants ‘often’ or ‘very often’ needed ‘extra explanation to understand 
the project’, had specific needs related to ‘low levels of literacy’ and ‘increased levels of anxiety 
related to current health situation’. All stakeholder groups felt it was important to keep most of the 
current informational content in some way within the materials but suggested changes to the PIS 
and consent documents in terms of presentation and readability.  
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The following recommendations are made to Genomics England and are 
based on the evidence from this evaluation. It is expected that Genomics 
England will take forward the conversations with partners across the 
healthcare system such as NHS England, Genomic Medicine Centres and 
Health Education England. 
Recommendations 1 to 8 are suggestions on elements to maintain, recommendations 9 to 17 are 
issues Genomics England may consider changing in relation to project documentation, and 
recommendations 18 to 26 are linked to project processes. Each recommendation is linked back to 
the data collected by providing the recommendation number alongside the evidence within the 
synthesis tables in Chapter 4. 
Things to maintain (1-8) 
1. The current range of consent materials i.e. participant information sheet (PIS), consent forms, 
information leaflet, animation/flip chart. 
2. The current wording in the PIS relating to explanations of scientific and genomic terminology in 
line with recommendation 9. 
3. The majority of the information content within the PIS (responses from participants and most 
focus group members support this, along with 50% of recruiters). 
4. The PIS both in paper form and on-line (not just on-line). 
5. The key point boxes and colour on the forms. 
6. Continue to develop accessibility to consent materials for low vision patients.  
7. The ability of participants to opt-in and opt-out of the search for additional findings. 
8. The facility for health professionals to have the time to adequately discuss and answer patient 
questions prior to the consent decision. 
Changes to Consider - Project Documentation/Accessibility (9-16) 
9. Improve the presentation and readability of the PIS and consent forms in the following ways.  
9.1 Reduce the density of words. 
9.2 Reduce replication of text especially the sections between the consent form and PIS and 
also after the key point boxes. 
9.3 Use pictures/diagrams where possible. 
9.4 Work with participants/100,000 Genomes Project National Participation Panel/PPI 
groups/Ethics Advisory Committee to review new material/changes to assist in approaching 
standards such as the plain English guidelines and the Accessible Information Act. 
9.5 Reduce the length of the consent form. 
9.6 Review the terminology (e.g. main findings, additional findings) used across all project 
materials, including written and animation/video to assist with understanding the project 
specific terms. 
9.7 Include a source for standard definitions/concepts (this could also be available for 
recruiters) for example, a glossary of definitions of both scientific and project terminology 
and ensure these are consistent with descriptions in the text. 
10. Continue to support non-English speakers by promoting the use of existing NHS translation 
services when discussing project documentation with potential participants. 
11. Produce an ‘Easy Read’ version of the PIS and consent form that could be used for participants 
with reduced intellectual ability or  those for whom English is a second language (possibly the ‘young 
adults’ PIS could be adapted for use with this group). 
National Evaluation Project Report | November 2016 
 
Page 53 of 55 
 
12. Provide an audio/video of the content of the PIS and consent form for participants who find 
access to the written word difficult. 
13. Promote the Genomics England website as a place to access information (presented in a variety 
of formats) about taking part in the project. 
14. All materials to adopt consistent use of terms relating to anonymisation, when is it linked-data, 
when unlinked and clarify at which point this occurs e.g. at what point companies might have access. 
15. More information to be available to participants regarding the concept of additional findings and 
especially ones of reproductive significance, including the timescale for results and future contact. 
16. To clarify the audience for the tri-fold information booklet and if it is for use with patients, 
review the booklet and add definitions of terminology used.  
 
Changes to Consider - Process of Consent Interaction (17-22) 
17. Explore ways of ensuring that recruiters have appropriate time to discuss the issues raised in the 
PIS with participants, where this is needed. 
18. Support recruiters through on-going consent training including how to manage questions from 
participants regarding support with communication in their families and social/psychological 
support. 
19. Support recruiters in the information technology systems for registering participants and logging 
samples. 
20. Provision of more publicity materials to help recruitment into the project. 
21. A staged consent process for cancer participants if anxiety levels are high at the time of 
diagnosis. Possibly consider adapting the PIS and consent forms for this patient group. 
22. In the further integration of whole genome sequencing into routine NHS clinical care, the 
following issues need careful consideration and planning. 
22.1 Maintaining adequate time for consent discussion. 
22.2 Consider carefully the changes required for the transition of Whole Genome 
Sequencing consent from the research environment into routine clinical care. 
22.3 Supportive appropriate local mechanisms for receipt of main findings and additional   
findings (results). 
22.4 Support and updating of staff providing patient support.  
22.5 Consideration of consent timing within the routine care pathway (especially cancer 
patients and their families). 
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Glossary 
Consent documentation 
Any material produced by Genomics England to provide potential participants with information 
about participation in the 100,000 Genomes Project (including all REC approved materials) and also 
the consent forms used for the participant to provide evidence of consent.  
 
The consent discussion process 
This includes how potential participants (existing NHS patients and their family members) became 
aware of the 100,000 Genomes Project, their interaction with health professionals with whom they 
might discuss the project, and also health professionals who are involved with facilitating the 
discussion and documenting informed consent. 
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